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Abstract
Professional phagocytes are white blood cells of the innate immune system that protect humans and
other animals from attacks by foreign pathogens by ingesting potentially harmful circulating particles.
However, phagocytes such as macrophages may also attack elements that have been intentionally
introduced into the body, such as implants, artificial tissues, artificial organs and vesicles bearing
therapeutic agents, reducing their lifetime in the body. Nanoparticles and liposomes are similar in size to
viruses, and are frequently decorated with antibodies for targeted therapeutics or imaging purposes.
Although such particles are sufficiently small to avoid passive entrapment within capillaries in vivo,
macrophages in the spleen and liver are known to clear these particles within hours or days after injection
into the circulation, limiting proper delivery to target disease sites. This dissertation describes the
engineering of long-circulating nanoscale carriers bearing a universal marker that avoids macrophage
clearance by mimicking the process of recognition of ”self”cells in vivo. The membrane protein CD47 is a
marker of ”self” that impedes phagocytosis of ”self” cells by signaling through a species-specific, highly
polymorphic receptor named SIRPα. Among natural mouse variants, only NOD.SCID gamma chain (NSG)
mice express a mouse polymorph of SIRPα that cross-reacts with human CD47, and thus provided an
ideal platform for our in vivo assessment of human CD47 on synthetic particles. Based on the cocrystallized structure of the CD47-SIRPα complex, polypeptides were designed by simulation and then
synthesized with the further reductionist goal of identifying and then exploiting the most minimal
components necessary for CD47-SIRPα complex interactions. This thesis details a reductionist approach
that avoids many potentially confounding biological factors, and constitutes a first example of a
synthetic, human ligand that is easily attached to synthetic surfaces and can successfully mediate
binding and signaling to phagocyte receptors to inhibit phagocytic uptake. By understanding how both the
full-length as well as the minimal component of the hCD47-SIRPα interaction works in vivo, this
dissertation was able to elucidate potential therapeutic roles for anti-hCD47 antibody targeting in
biodistribution of drugs delivered to solid tumors, among other applications.
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ABSTRACT

VIRUS-SIZE NANOPARTICLES COATED WITH A SYNTHETIC “SELF”
PEPTIDE INHIBIT PHAGOCYTIC CLEARANCE AND ENHANCE DELIVERY OF
AN ANTI-CANCER DRUG

Pía Lorena Rodríguez Núñez

Dr. Dennis E. Discher

Professional phagocytes are white blood cells of the innate immune
system that protect humans and other animals from attacks by foreign pathogens
by ingesting potentially harmful circulating particles. However, phagocytes such
as macrophages may also attack elements that have been intentionally
introduced into the body, such as implants, artificial tissues, artificial organs and
vesicles bearing therapeutic agents, reducing their lifetime in the body.
Nanoparticles and liposomes are similar in size to viruses, and are frequently
decorated with antibodies for targeted therapeutics or imaging purposes.
Although such particles are sufficiently small to avoid passive entrapment within
capillaries in vivo, macrophages in the spleen and liver are known to clear these
particles within hours or days after injection into the circulation, limiting proper
iv

delivery to target disease sites. This dissertation describes the engineering of
long-circulating nanoscale carriers bearing a universal marker that avoids
macrophage clearance by mimicking the process of recognition of “self” cells in
vivo. The membrane protein CD47 is a marker of “self” that impedes
phagocytosis of “self” cells by signaling through a species-specific, highly
polymorphic receptor named SIRPα.

Among natural mouse variants, only

NOD.SCID gamma chain (NSG) mice express a mouse polymorph of SIRPα that
cross-reacts with human CD47, and thus provided an ideal platform for our in
vivo assessment of human CD47 on synthetic particles. Based on the cocrystallized structure of the CD47-SIRPα complex, polypeptides were designed
by simulation and then synthesized with the further reductionist goal of identifying
and then exploiting the most minimal components necessary for CD47-SIRPα
complex interactions.

This thesis details a reductionist approach that avoids

many potentially confounding biological factors, and constitutes a first example of
a synthetic, human ligand that is easily attached to synthetic surfaces and can
successfully mediate binding and signaling to phagocyte receptors to inhibit
phagocytic uptake. By understanding how both the full-length as well as the
minimal component of the hCD47-SIRPα interaction works in vivo, this
dissertation was able to elucidate potential therapeutic roles for anti-hCD47
antibody targeting in biodistribution of drugs delivered to solid tumors, among
other applications.
v
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CHAPTER 1: Introduction to CD47-SIRPα

1

1.1 – Background

The immune system has evolved to counteract assault on the body by
non-“self” entities that may compromise an individual’s health. This tight
regulation involves complex interactions between membrane proteins on
Macrophages that play key roles in both the innate and adaptive immune
responses. Viable cells are normally not phagocytosed since CD47 on their
surface can interact with the phagocytosis inhibitor receptor signal regulatory
protein alpha (SIRPα) on the macrophage (Oldenborg 2000). Both CD47 and
SIRPα are critical aspects of this doctoral dissertation, and therefore we start by
providing some important background information on both of them.
The ubiquitously expressed protein CD47 is an Ig superfamily member
that interacts specifically with SIRPα found on macrophages (Jiang 1999; Seiffert
1999; Vernon-Wilson 2000) and innate immune cell as a regulator or toll receptor
signaling (Kong 2007). CD47 interacts with signal regulatory protein-α (SIRPα),
thrombospondin (TSP)-1 and -2 to mediate various cellular functions (Oldenborg
2001). In particular, CD47 signaling through SIRPα inhibits the phagocytosis of
CD47-expressing

target

cells

by

SIRPα-expressing

macrophages.

Phosphorylation of the immune-receptor tyrosine-based inhibitory motif (ITIM) in
the cytoplasmic domain of SIRPα upon ligation with CD47 leads to the
recruitment of SHP-1 and deactivation of phagocytosis (Vernon-Wilson 2000;
2

Seiffert 2001). The loss of CD47 protein in red blood cells (RBCs), platelets,
apoptotic cells and lymphocytes results in their rapid elimination by splenic
macrophages (Oldenborg 2001; Krieser 2002; Oldenborg 2004, Gardai 2005;
Majeti 2009). Anti-CD47 monoclonal antibodies inhibiting the interaction of CD47
and SIRPα promote the phagocytosis of tumor cells by macrophages, and also
by monocytes and neutrophils (Gresham 1989, Jaiswal 2009).

Anti-CD47

monoclonal antibodies have been shown to inhibit phagocytosis in vitro and
significantly inhibit myeloma growth in human fetal bone-free and –bearing
xenotransplantation models in vivo (Kim 2012).
The receptor SIRPα is composed of three immunoglobulin superfamily
(IgSF) domains while CD47 contains only a single IgSF domain with a disulfide
link across one of the loops between the transmembrane regions (Tsai 2008),
which may be required for optimal binding of SIRPα. The crystal structure of the
SIRPα-CD47 complex indicates a high degree of flexibility in the SIRPα loops,
and that CD47 binds SIRPα at its N-terminal ligand-binding domain (Hatherley
2008).
Expression of both SIRPα and CD47 on the surface of macrophages
raises the possibility that these proteins interact on the same macrophage
surface (in cis). The occurrence of cis interactions would have implications for
SIRPα’s ability to bind to CD47 on target cells (in trans) (Doucey 2004).

3

CD47 binds to SIRPα with relatively low affinity, and the interaction does
not result in strong cell-cell adhesion (Hatherley 2007; Subramanian 2007). The
lower affinity interaction of CD47-SIRPα instead allows for transient cis or trans
interactions during intracellular or intercellular binding. CD47 expression is not
limited to red blood cells, being present in many other cell types including
macrophages. SIRPα belongs to the “paired receptors” class of membrane
proteins, and exhibits homology to other receptors on innate immune cells
including natural killer (NK) cells, as well as to major histocompatibility complex
(MHC) proteins (Lanier 2005).
Recently, research on the high degree of polymorphisms in the SIRPα Nterminal domain reported by Takenaka et al. (2007) implicated the SIRPα locus
in the more efficient engraftment of human bone marrow stem cells into the nonobese diabetic severe combined immunodeficiency (NOD.SCID) mouse strain
over other strains. In general, there is little cross reaction between CD47 from
one species and SIRPα of another (Subramanian 2006, 2007). However, the
allele of SIRPα in the NOD.SCID mouse is sufficiently different from other mouse
strains to enable binding to human CD47 and mediate protection of human cells
from host macrophages, allowing for xenogenenic engraftment. (Barclay 2009).
Recent studies have showed that some transgenic BALB/c mice exhibited
increased engraftment of human hematopoietic cells improved functionality of the
human immune cells over NOD.SCID, and NOD.SCID gamma (NSG) mice
4

(Strowig 2011, Legrand 2011). However, further analysis of the SIRPα proteins in
these strains need to be done to show the binding affinity constant of those
SIRPα to hCD47. In this dissertation, we have adopted a conservative approach
by electing to utilize the NSG strain as the host in which to study the CD47SIRPα interaction.

1.2 – Motivation for reductionist approach with particles

A major challenge in injecting particles or implanting biomaterials into the
body is the possibility that they will activate an immune response. The
internalization of extracellular material into cells is commonly performed by a
process called endocytosis, which is divided into two general categories:
phagocytosis, which involves the uptake of particles, and pinocytosis, which
involves the uptake of fluid and solutes. Phagocytosis is an essential arm of the
immune response whose main function is to clear and destroy invading
pathogens (Allen 1996). This chore is conducted primarily by highly specialized
cells, such as macrophages, monocytes and neutrophils, with the goal of clearing
pathogens and/or debris (Stuart 2008). Interestingly, macrophages have a
surface receptor mechanism which prevents them from phagocytosing one’s own
“self” cells. During initial macrophage engulfment, macrophages recognize both
foreign and “self” targets because both display antibodies or plasma complement
proteins on their surface. However, before macrophage engulfment, “self” cells
5

are checked for the presence of the surface protein CD47. While it has been
shown that macrophages are efficient at discriminating between foreign cells and
particles in the micrometer size range (Tsai 2008), little is known about how this
“self” signal, CD47, behaves in targets that are less than 500 nanometers in size.
In fact, particles that are in the nanometer length scales may undergo a process
other than traditional phagocytosis (Wright 1984, Koval 1998; Rejman 2004).
Therefore, new research is needed in order to enhance our understanding of how
macrophage targets use the CD47 “self” signal in the nanometer range, which is
precisely the focus of this dissertation. In this thesis work, we employ a
reductionist approach by designing short peptides that can easily attach to
nanobeads.

This allowed us to quantify binding to and signaling of these

peptides as well as of soluble-CD47 to its receptor, SIRPα. Inhibition of
phagocytosis mediated either by peptide-coated or by CD47-coated beads was
also quantified, as well as the beads’ in vivo clearance kinetics in NSG mice.

1.3 – Phagocytosis after opsonization

The extent of macrophage signaling induced by the interaction between
CD47 ligand to its receptor SIRPα is affected by the expression levels of both
proteins. Macrophages sense foreign and self through SIRPα recognition of self
protein, CD47 on target cells stimulate tyrosine activation of the immune-receptor
tyrosine-based inhibitory motif (ITIM) which leads to recruitment of SHP-1 and
6

subsequent deactivation of cytoskeletal proteins (Tsai 2008). The process of
phagocytosis is often activated when opsonins such as antibodies attach and are
recognized by Fc receptors (FcR). Foreign cells and viruses as well as autologous
cells are typically Ig-opsonized by antibodies (McCullough 1988; Turrini 1993;
Wilflingseder 2007). Also, since particles are rapidly cleared whenever an
antibody is added to a nanoparticle, the tradeoff between the amount of Opsonin
and CD47 protein added onto particle surfaces needs to be studied. For our
purposes, as NSG mice lack IgG and since IgG is one of the three most
commonly adsorbed serum proteins, we added the IgG opsonin to the
nanobeads before injection in order to render the system more analogous to
normal animals and humans.
Similarly, in order to study the effect of the ligand-receptor interaction in
phagocytosis after opsonization, we designed an experimental system in which
sheep and human red blood cells (RBC) were IgG-opsonized and fed to
macrophages. We found that the opsonization levels linearly correlated with antiserum dilution (Fig 1.1), while phagocytosis of sheep RBC by human-derived
THP-1 macrophages was non-linear, exhibiting a response that could be
saturated.
This is consistent with one of our previous findings (Tsai 2010) wherein
opsinized particles were fed to human or mouse macrophages that lacked
membrane proteins such as Rh proteins. The particles were avidin-coated and
7

IgG-opsonized with anti-streptavidin in order to allow for FcγR-mediated
phagocytosis. Human macrophages phagocytosed the uncoated, “CD47-null”
beads significantly more than beads displaying hCD47. The two ligands, CD47
and IgG-opsonin, do not compete and do not interfere with SIRPα binding (Tsai
2008). Thus, the dependence on the level of IgG-opsonization fit that of a
saturating binding process, which was indicative of the specificity of Fcγ-R
mediated phagocytosis, as seen with RBC.
The “decision” of a macrophage to phagocytose a target is in part made
by assessing the extent of target opsonization. Ig concentrations are typically
very high in bodily fluids, which seems to lead to absorption or at least weak
binding in some level to all cells (Turrini 1993)-- especially aged blood cells
(Fossati-Jimack 2002). Our binding, signaling, and phagocytosis results
motivated additional characterization of CD47 expression levels on all cells
involved, especially in light of changes in CD47 expression levels that are seen
on hematopoietic stem cells (HSC) (Jaiswal 2009).

8

Fig.1.1.- Phagocytosis
gocytosis of Ig
Ig-opsonized sheep RBC by human-THP-1
human
macrophages.
(A) Fresh sheep and human RBC were incubated with anti
anti-serum
serum at different
dilution ratios and detected by FITC
FITC-anti-RBC,
RBC, exhibiting a linear opsonization
based on flow cytometry. (B) Phagocytosis of shRBC by human-derived
human
THP-1
macrophages at different op
opsonization
sonization level observed by DIC microscopy
showed
d a saturable type of response
response.
The goal of this dissertation was to design polypeptides that could avoid
species-specific clearance to enhance xenotrasplantation. We quantified CD47SIRPα binding by inves
investigating
tigating the inhibitory mechanisms of phagocytosis and
9

their implications in body clearance. Based on recent research and collaborative
work with former graduate students, we followed a bottom-up approach to study
this “self” recognition protein. CD47 was used to study the phagocytic
mechanism in macrophages. We were able to show a species-specific
recognition of “self” by using RBC from sheep and humans as non-“self” and
“self” targets in vitro. We also developed a mathematical model to understand the
trans and cis interactions of the “self”-receptor SIRPα in macrophages that
expressed CD47, and how the cis interaction may impede the ability to effectively
differentiate between “self” and non-“self” due to inherent inhibitory signals.
As part of the innate immune response neutrophils are also involved in
phagocytosis of non-“self” targets. Neutrophils, as with all phagocytizing immune
cells, are strongly driven to phagocytose by the presence of opsonins such as
antibodies, highlighting the cooperative nature of the innate and adaptive
immune responses. Therefore, we extended our studies of phagocytosis into
migration effects of hCD47 and “self” peptide on neutrophils.
We also explored the species-specific interaction of SIRPα-CD47 with
NSG macrophages and RBCs in order to determine the effects of affinity and
phagocytosis in the clearance process of foreign nanoparticles by the immune
system. Finally, we explored the potential for enhanced imaging of tumors with
near-infrared nanobeads conjugated with hCD47 or “self” peptide. If tumor
perfusion of the particles and the subsequent enhanced permeability and
10

retention (EPR) effect of immune system evasion were increased, there would be
potential

for

biomedical

applications.

Specifically,

we

studied

whether

recombinant hCD47 protein or the small synthetic “self” peptide could enhance
the effects of an anti-cancer drug and whether it could improve the delivery of
nanoparticles to tumor sites when they contained bioactive antibodies against a
therapeutic target.
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CHAPTER 2 - ‘Active Stealth’ signaling with a synthetic “self”
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Abstract

Foreign particles and cells are rapidly cleared from the body by
professional phagocytes that incessantly encounter and recognize “self” cells.
The membrane protein CD47 appears to be a ‘Marker of Self’ that impedes
phagocytosis of self cells, with signaling through a species-specific, highly
polymorphic receptor, SIRPα. Here, minimal “self” peptides were computationally
designed from human-CD47, synthesized with anchoring groups, and attached to
virus-size nanoparticles for injection into NOD.SCID (NSG) mice that are known
to exhibit unique compatibility with human cells.

The hCD47-peptides delay

splenic clearance of particles by macrophages with an exponential advantage in
persistent circulation. The affinity of hCD47 for NSG-SIRPα proves weak but
within the broad range (0.1~5 µM) measured for ten constructed variants of
human-SIRPα; several versions of hCD47-peptide are likewise shown to bind
and potently inhibit nanoparticle uptake by an unexpected cytoskeletal
mechanism. The reductionist approach reveals the importance and utility as well
as some limits of a human ‘Marker of Self’.

2.1 – Introduction

Macrophages engulf invading microbes and dying cells in a highly
coordinated and active process that evolved over eons and occurs also now in
foreign body responses to injected particles and implants. This clearance
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function of phagocytes is delayed but not eliminated by dense ‘Stealth’ brushes
such as with polyethylene glycol (PEG) on circulating nanoparticles and
liposomes used in therapeutics and imaging (Klibanov 1991, Photos 2003,
Bartlett 2007).

Coating with PEG of (<500 nm) indeed helps to delay rapid

clearance and to thereby provide more time for circulation through disease sites
such as tumors, but neither PEG nor targeting groups can stop the clearance of a
majority of particles from the circulation by macrophages in the spleen and liver
(e.g. Klibanov 1991, Photos 2003, Turk 2004, Bartlett 2007, Rossin 2008).
Delivery to disease sites can also be limited by phagocytic uptake by tumorassociated macrophages for example (Turk 2004), and the acquired immunity to
foreign polymers has become an additional concern (Armstrong 2007).

In

contrast, “self” cells and tissues are in constant contact with and well-tolerated by
macrophages, which has suggested critical mechanisms of self recognition.
Here we describe a reductionist approach to a synthetic but humanized “Active
Stealth” peptide that specifically binds and signals “self” to phagocytes in
blocking clearance of particles as small as viruses.
CD47 glycoprotein is a putative ‘Marker of Self’ (Oldenborg 2000) normally
expressed on all cell membranes in humans, mice and other higher organisms
(Bentley 2010), and it often associates in cis with integrins (Brown 2001) and in
other species-specific, immunogenic macrocomplexes on cells (Bruce 2003,
Mouro-Chanteloup 2003, Subramanian 2006)
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Mouse knockouts of CD47

(mCD47) are surprisingly viable, but when red blood cells from these mice
(mRBCs) are injected into the circulation of control mice, the deficient cells are
cleared within hours by macrophages of the spleen compared to normal mRBC
that circulate for weeks (Oldenborg 2000). CD47’s extracellular domain interacts
with SIRPα (Signal Regulatory Protein-α) on phagocytes (Brown 2001), and the
binding is species-specific (Subramanian 2006) in part because SIRPα is highly
polymorphic within a species (Takenaka 2007). Indeed, NOD.SCID strains of
mice happen to express one variant of mouse-SIRPα that cross-reacts with
human-CD47, which explains why human hematopoietic cells engraft and
circulate in NOD.SCID better than any other mouse strain (Takenaka 2007,
Strowig 2011). In vitro, the CD47-SIRPα interaction inhibits mouse macrophage
uptake of antibody-coated mRBCs (Oldenborg 2000) as well as human
macrophage uptake of both human-RBC and human-CD47 (hCD47)-coated
microparticles (Tsai 2008). SIRPα signaling ultimately inhibits contractility-driven
uptake of micron-size cells and particles (Tsai 2008), but while contractile forces
exerted by the cytoskeleton are sensible for uptake of such large objects they are
widely considered unimportant to internalization of nanoparticles and viruses.
We address whether human-CD47 and a synthetic “self” peptide on such
small particles can minimize phagocytic uptake and thereby enhance delivery in
vivo here using NOD.SCID/Il2rg-/- mice (NSG).

Our reductionist approach

eliminates confounding, biological factors on cell membranes (e.g. integrins), and
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the results with a minimal “self” peptide constitute a first example of a synthetic,
human ligand that binds and signals to phagocyte receptors to passivate
macrophages.

2.2 – Results

2.2.1 – Human CD47 and a “self”-peptide prolong circulation of
nanoparticles in vivo
To check that CD47 is effective in the NSG mouse strain and to also
establish a method for comparing circulation times, we first sought to show that
blocking of mCD47 accelerates clearance of mouse-RBCs in NSG mice.
Competitive circulation studies were designed to maximize accuracy in
quantitation for each mouse (Fig. 2.1A), with cells (or nanobeads) split into two
samples with one sample labeled by red fluorophore and the other sample
labeled by far-red fluorophore plus anti-mCD47. The samples were then mixed
1:1 for injection into the same mouse. Bleeds at subsequent time points
(including t = 0) are analyzed by flow cytometry for both colors (Fig. 2.S1A),
providing a ratio result that minimizes variations mouse-to-mouse. Since NSG
mice lack serum IgG (~100 µM in normal mice), cells were also heavily
opsonized by anti-mRBC to controllably accelerate clearance via phagocytosis
(Cox 2001). IgG is also found in abundance on normal RBC in vivo (Turrini
1993) as well as on nanoparticles (Lundqvist 2008) and on viruses (Wilflingseder
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2010), and so clearance signals are ever-present. Consistent with a ‘Marker of
Self’ function of mCD47, the persistence ratio for the mixed sample [mRBC /
(mRBC with blocked mCD47)] increased exponentially (R2 = 0.93) with a
doubling time of T = 33 min (Fig. 2.1B); single color results give T = 30 min (Fig.
2.S1B), such a doubling time advantage sustained over one full day would yield
~10-trillion more RBC with CD47 (= 224h/33min) compared to every circulating RBC
without CD47. This exceeds the daily production of RBCs in humans by about
100-fold and begins to suggest the potency of CD47 and/or co-factors on RBC.
RBC membranes are complicated with hundreds of different interacting
proteins, and some involved in clearance are distinct between mouse and man
(Mouro-Chanteloup 2003, Glodek 2010). Beads have much better defined
surface properties and enable addition of ‘Marker of Self’ ligands, but it is wellappreciated that rigid beads must be far smaller than highly flexible RBC to avoid
first-pass clearance from the microcirculation (Deplaine 2010). Nanoparticles are
thus needed but can be a challenge to characterize in vivo. The extracellular, Iglike domain of human-CD47 (hCD47) that binds SIRPα was recombinantly
expressed, site-specifically biotinylated, and then bound to Streptavidin-coated,
160 nm polystyrene nanobeads for in vivo and in vitro studies. Beads were also
labeled with red or near-infrared dyes (or left unlabeled) and opsonized equally
with anti-Streptavidin before injection into the tail-vein of an NSG mouse. Whole
blood analysis by flow cytometry clearly identified these nanobeads in the
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circulation based on both distinctive scatter and fluorescence detection of antiStreptavidin (Fig. 2.1A, inset; Fig. 2.S1C). The persistence ratio for
(Nanobead+hCD47 / Nanobead) is again well-controlled at every time-point and
increases exponentially with a relative doubling time T = 30 min (Fig. 2.1C),
which is about the same as mouse-RBC above ("doubling time" for beads does
not refer to an actual ability to replicate, but is instead used as an analogy to
demonstrate that beads behave similarly to RBC). Mice injected with just a single
color of nanobead gave similar results (Fig. 2.S1D). In order to test whether any
other opsonins would have similar effects in circulation, we tested a targeting
antibody that yielded similar results (Fig. 2.S1E). As one of two controls, PEGbiotin modified beads gave a flat persistence curve with T > 200 min (Fig. 2.1C,
Fig. 2.S2B).

Additionally, longer circulation studies with PEGylated particles

(Fig. 2.S2A) provided some evidence that adding CD47 to these particles
increase the circulation time in vivo even when targeting or opsonizing antibodies
are not pre-attached onto the beads, which correlates with the phagocytosis
assays in vitro (Fig. 2.S2D). Human-CD47 on virus-size nanoparticles thus acts
as an inhibitor of in vivo clearance, thereby prolonging circulation.
Minimizing the 117 amino acid, recombinant hCD47 domain to a binding
site peptide could provide, we thought, the clearest evidence that binding and
signaling of hCD47 to mSIRPα is the molecular mechanism of inhibition in vivo.
Mouse and human CD47 differ by about 40% in the sequence of SIRPα’s N20

terminal domain, and these differences include one or more amino acids in each
of three distinct binding sequences in the co-crystal structure of hCD47-hSIRPα
(Hatherley, 2008). Multiple mutations in each sequence decrease binding
substantially (Hatherley, 2008), but the highest density of interactions with
hSIRPα are in one loop in hCD47 between canonical β-strands ‘F’ and ‘G’, where
a nine amino acid sequence constitutes 40% of hCD47’s contacting residues.
Our first guess design was a 21 amino acid “self”-peptide, which was simulated
for stability and interactions (see below) and then synthesized with the aims of (i)
minimizing species specificity (Strowig 2011), (ii) eliminating the glycosylation of
CD47 that impedes binding (Subramanian 2007), and (iii) developing Scrambled,
inactive peptides. Biotinylation on an amino-terminal PEG linker provided a
means of attachment to Streptavidin-beads for in vivo studies. Surprisingly, the
“self”-peptide increased persistence of beads in the circulation compared even to
recombinant hCD47: the faster growing exponential has a 40% smaller doubling
time of T = 18 min compared to control nanobeads (Fig. 2.1C). In comparison,
Scrambled-peptide has little impact on circulation, which suggests specificity to
interactions as analyzed in detail below for these and additional synthetic
designs. An apparent difference between hCD47 and ‘Self’ peptide is not
significant (p = 0.18).
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α weakly but within a broad range of
2.2.2 – hCD47 binds NSG-SIRPα
affinities for human polymorphisms
Flow cytometry enables detailed analysis of the surface of nanobeads
before injection (Fig. 2.S2C) and in blood drawn at various time points postinjection. While anti-streptavidin IgG remains stably bound to beads, a fraction of
the biotinylated-hCD47 is often lost from the bead surface (30% in Fig. 2.2A,
inset bargraph; Fig. 2.S4A), even though the biotin part of the protein was
strongly attached to avidin present on the bead surface. This could be due to the
presence of a biotinylase enzyme in circulation that has been shown to
compromise avidin:biotin binding (Kuroishi 2008; Jeong Lee 2000). Thus, CD47
could be binding free biotin upon detaching from the beads. Covalent attachment
of biotinylated-hCD47 might ameliorate this problem. Nonetheless, the %Clearance of nanobeads at 35 min versus the measured density of hCD47 at 35
min fit well to a simple inhibition model that also fits our “self”-peptide results
(Fig. 2.2 A) with:
Ki,in-vivo = 110 molecules per 160 nm Nanobead
This appears independent of circulating bead number over at least a ~tenfold range (Fig. 2.S4 B).This corresponds to a density of hCD47 that is about
ten-fold higher than the lowest densities reported for human RBC (i.e. ~25
hCD47 molecules/µm2 (Mouro-Chanteloup 2003)). Indeed, saturable binding of
soluble hCD47 to fresh, NSG-SIRPα+ phagocytes yields a weak, effective affinity
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of just Kd = 4 µM (Fig. 2.2B). Lymphocytes do not express SIRPα (Seiffert 1999)
and show no binding to CD47.
To compare the affinity for NSG-mouse to human-SIRPα (hSIRPα), ten
reported human polymorphic variants of hSIRPα (Takenaka 2007) were
constructed here as C-terminal GFP fusions and expressed on CHO cell
membranes as done previously with CD47-GFP (Subramanian2007). Many of
the amino acid changes in SIRPα occur near but not in the hCD47 binding site
(Hatherley 2008), making predictions difficult. Saturation binding of soluble
hCD47 to each variant yields a surprisingly broad, 60-fold range of affinities with
Kd = 0.08 − 5 µM (Fig. 2.2C). Soluble protein showed the same trend (Fig. 2.S5).
The co-crystal structure of hCD47-hSIRPα shows all of the amino acid
differences in these variants occur outside of the binding interface (Hatherley
2008), and so the effects here seem likely to reflect allosteric and conformational
mechanisms, including SIRPα homodimers (Lee 2010). When plotted versus
human allele frequency of SIRPα, variants of intermediate affinity (e.g. v1, v2)
are most common and are similar to results for soluble- SIRPα(v1) binding to
CHO-displayed hCD47-GFP (Subramanian 2007). Importantly, the 4 µM affinity
for NSG-SIRPα phagocytes proves weak but within the range of ten human
variants, consistent with the cited success of human xenografts in NOD.SCID
mice.
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In addition, to show that the CD47-SIRPα interaction is indeed involved in
the delay of clearance of the beads in vivo, we blocked mouse-SIRPα in NSG
mice by pre-injecting anti(mSIRPα) antibodies that block binding of mSIRPα to
CD47 in vitro. After nanoparticles were injected to these pre-injected mice, the
circulating particle ratio at 35 min was measured as in Fig. 2.2A. CD47 particles
provided no advantage in circulation (Fig. 2.2B, inset) when blocking SIRPα
antibody is bounded to splenic macrophages.

2.2.3 – Minimal “self”: conformational constraints limit activity
Given the important, allosteric effects of SIRPα variants on affinity for
hCD47, the impact of “self”-peptide conformation on binding and signaling is
conceivably just as important. The recent co-crystal structure of the hCD47 Iglike domain in association with the hSIRPα Ig-like domain suggested important
electrostatic interactions of the “self”-peptide’s loop, but stability of this hairpin
was unknown and seemed important to binding. Three versions of the peptide
were therefore designed and simulated by all-atom Molecular Dynamics (Fig.
2.2D; Fig. 2.S6): (i) the 21-aa “self”-peptide that was shown functional above,
and also (ii) a 12-aa “self”-SS-peptide with a T107C substitution opposite in the
hairpin to C96 intended to disulfide-stabilize the β-hairpin, together with (iii) a 10aa “self”-hairpin centered on the loop. Equilibration of the three peptide designs
and also hCD47 respectively show that, relative to the “self”-SS-peptide, the
“self”-peptide maintains a smaller β-hairpin (Fig. 2.2D, upper plot) that achieves
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more salt bridges in docking simulations with hSIRPα (Fig. 2.2D, lower plots).
The “self”-SS-peptide undergoes a large torsional distortion that alters the
surface charge distribution, whereas the short “self”-hairpin completely loses its
initial loop but is not over-constrained in a misfolded state.
Synthesis of the three designs and Scrambled-peptides (with or without
biotin attached via a PEG linker or an aminohexanoic acid linker ‘C6’), enabled
functional testing of binding to hSIRPα as well as inhibition of nanobead
phagocytosis.

When immobilized on beads, the “self”-peptide’s affinity for

soluble hSIRPα (Kd ≈ 0.1-0.2 µM; Fig. 2.2E-i,ii) proves high on the affinity scale
for polymorphisms (Fig. 2.2C) and consistent with functionality of peptide in vivo
(Fig. 2.1) and in vitro (see below). In contrast, the disulfide-stapled “self”-SSpeptide showed no significant affinity for hSIRPα and no statistically significant
inhibition of phagocytosis, thus revealing the importance of flexibility in
maintaining the β-hairpin’s surface charge distribution. While the PEG linker
between biotin and peptide improves solubility, the more hydrophobic C6 linker
has little impact on hSIRPα binding, whereas scrambling the peptide eliminates
binding as well as any statistically significant inhibition of phagocytosis (Fig.
2.2E-ii).
The 10-aa “self”-hairpin was also synthesized without attachment of biotin
for use as a soluble inhibitor of hSIRPα binding to hCD47-beads. While the
scrambled peptide lacked function once again, this short “self”-hairpin inhibited
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hCD47-hSIRPα interactions, and although the extent of inhibition was less than
with the longer “self”-peptide, a similar Ki ≈ 0.1 – 0.2 µM (Fig. 2.2E-iii) proves
consistent with the affinities measured above. The results all substantiate the
general approach to specific binding and signaling (see below) from a minimal
‘Marker of Self’ peptide.

2.2.4 – In vivo persistence of “self” correlates with inhibition of
phagocytosis in vitro.
Whether phagocytosis of nanoparticles – including viruses – involves
mechanisms similar to larger particles remains a significant question in the field
of phagocytosis (Swanson 2004), and CD47 on nanobeads here could help
clarify the minimal limits to phagocytic uptake. The spleen generally clears
nanoparticles (Fig. 2.S3A-D), and fluorescence imaging of tissue sections shows
the strong tendency of nanobeads to colocalize with macrophages (Fig. 2.3A,
inset-i), consistent with the well-established role of the mononuclear phagocyte
system. Human-derived THP1 macrophages express one of the common
variants of hSIRPα (v1), which is why hCD47 has been reported to inhibit
phagocytosis of microparticles by these cells in vitro (Tsai 2008). Nanoparticles
are not sufficiently large or dense to settle to the bottom of a culture dish, which
limits bead contact with such cells, but since binding is a surface-based process,
opsonized nanobeads that are added at the same total surface area as microbeads (Fig. 2.S7A) are seen to be taken up just as efficiently in culture by THP1
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macrophages (Fig. 2.3A, iia). Myosin-II accumulates at the phagocytic synapse
formed with opsonized beads except when hCD47 is attached to beads (Fig.
2.3A, iia-inset, iib). The result is similar to results with micro-particles and
microbes (i.e. bacteria) (Fig. 2.S7B).
The mechanism for inhibiting phagocytosis appears independent of
length-scale or curvature. Indeed, the amount of hCD47 required to impede
uptake in vitro by THP1 cells further proves independent of particle size from at
least 100 nm to 10 µm (Fig. 2.3A, iic; Fig. 2.S7C). Similar inhibition of nanobead
uptake was found with the biotinylated “self”-peptide, using two types of linkers,
whereas both Scrambled and “self”-SS peptides showed no significant inhibition
of phagocytosis (Fig. 2.2E, i,ii-insets). Inhibition with hCD47 is remarkably
potent with
Ki,in-vitro ≈ 1.0 ± 0.3 molecule / [4π( Equiv. Radius)2] for Equiv. Radius = 60nm.
This very low density of hCD47 is about the same as the lowest densities
reported for human RBC (Mouro-Chanteloup 2003), and despite the fact that
maximum inhibition for any particle studied here is incomplete (<80%), the above
Ki,in-vitro indicates that a nanoparticle of 60 nm Radius requires only 1 CD47
molecule to inhibit uptake. Nanobeads used throughout the studies here were
significantly larger to ensure that the vast majority of particles start with at least a
few molecules of hCD47, but the results highlight the potency of this ‘Marker of
Self’.
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Our previous knockdown and overexpression of myosin-II in THP1 cells
demonstrated that – unless hCD47 is on the target particles – IgG driven uptake
is linearly proportional to myosin-II activity (Tsai 2008). This is consistent with a
specialized and signal-responsive role for the cytoskeleton in phagocytosis (Cox
2001, Swanson 2004). With nanobeads here, hCD47 blocks uptake and so does
acute inhibition of myosin-II with blebbistatin (Fig. 2.3A, inset-iic). Myosin-II’s
enrichment near the nanobead extends deeply into the cytoplasm (~5 µm)
relative to bead size, suggestive of a diffuse signal that directs cytoskeletal
assembly. When CD47 binds SIRPα, Tyrosines in SIRPα’s cytoplasmic tail are
hyperphosphorylated and activate the hematopoietic-restricted phosphatase
SHP1 (Matozaki 2009) which dephosphorylates multiple proteins, including
myosin-II (Tsai 2008). Inhibition of SHP1 here produces the expected increase
in phagocytosis of hCD47-nanobeads as well as hCD47-microbeads (Fig. 2.3A,
inset-iic; Fig. 2.S7D). Consistent with inhibition of this signal in THP1
macrophages, binding of hCD47 and “self”-peptide leads to a significant increase
in phospho-SIRPα whereas Scrambled-peptide shows no significant effect
relative to controls (Fig. 2.3B). Consistent with a common mechanism in vitro
and in vivo, uptake of the various nanoparticles by THP1 cells correlates
inversely with persistence in NSG mice (Fig. 2.3C).
In vitro uptake by the human-derived THP1 cells (at 45 min) correlates
inversely with the in vivo persistence ratio in the NSG mice at a similar time point
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(y = 1/x, Fig. 2.3C). hCD47 inhibits the number of opsonized particles taken up
per cell in vitro by ~60% and “self”-peptide inhibits by ~75%, whereas PEG and
scrambled peptide lead to only a slight reduction in phagocytosis (average of
~25%). The results thus establish a major inhibitory effect and suggest that
potency might be engineered further with CD47-inspired peptides.

2.3 – Discussion

Phagocytes are found in all tissues of the body in addition to the spleen
and liver, and they have key roles in recognizing and clearing foreign cells and
particles as well as contributing to inflammatory responses with cytokine release
and oxidative burst. Recently we showed that implantation of polyurethane slabs
coated with hCD47 will inhibit oxidation of the polymer (Stachelek 2011),
indicating a general capacity of this ‘Marker of Self’ to passivate via active
signaling to Macrophages – a form of ‘Active Stealth’ (Fig. 2.4). A potency here
as low as 1 molecule per 60 nm particle is far smaller than the PEG densities
needed to inhibit phagocytes, and because CD47 is naturally expressed on all
cells, it seems far less likely to be as antigenic as PEG (Armstrong 2007).
The nanobead results suggest CD47 on viruses might also be useful or
important, especially since viruses are likewise cleared from circulation by spleen
and liver (Pan 2002). Initial results for HIV-related Lentivirus that display CD47GFP indeed show decreased infection of macrophages (not shown). Moreover,
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a putative homolog of CD47 encoded by at least one type of poxvirus has been
reported to maximize virulence (Cameron 2005). Structure analyses had
questioned interactions of the viral protein with SIRPα (Hatherley 2008), but the
minimal “self” peptides here lack amino acids that contribute in full length hCD47
to SIRPα binding, and yet binding is strong. Likewise, the ten human-SIRPα
variants here involve mutations far from the hCD47 binding site, and yet affinities
vary ~60-fold. Allosteric mechanisms are clearly in need of further study.
Whether CD47 or peptides are displayed on particles, viruses, or surfaces,
“self” signaling across length scales offers further opportunities in application as
well as understanding. In terms of molecular mechanisms and likely limits, the
synthetic “self”-peptide here works similar to or better than recombinant hCD47,
probably because the latter possesses five carbohydrate chains that inhibit
binding (Subramanian2007). On the other hand, conformation requirements of
the peptide will likely limit further reductionism (Fig. 2.2D). Based on the
polymorphism studies, an intermediate affinity for SIRPα is best and is
understandable (Fig. 2.2C) as a trade-off between adhesion that is not too strong
(‘must let go’) and signaling that is not too weak (‘don’t eat me’). Polymorphisms
in

CD47

have

been

recently

listed

in

databases

as

“damaging”

[www.1000genomes.org], but validation of these as well as the variants reported
for SIRPα are needed. Additionally, since CD47 is reportedly lacking in the
genome of amphibia and other lower species (Bentley 2010), and since the
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CD47-knockout mouse is viable if immune compromised (Oldenborg

2000),

additional and more ancient ‘Marker of Self’ proteins seem likely to contribute to
homeostasis in shifting the innate immune system further away from clearance
by macrophages in the liver, spleen, (tumors), and other tissues. Further
elaboration and application of “self” peptides might therefore help deliver imaging
agents and therapeutics more effectively to disease sites rather than to
phagocytes.

2.4 – Materials and Methods

2.4.1 – Chemicals
Streptavidin polystyrene beads were of different radius: 160nm, 1.1µm,
3.5µm, (Spherotech) and 100nm (Ademtech). Dulbecco’s phosphate-buffered
saline (DPBS) without Ca2+ or Mg2+ (Invitrogen) was supplemented with 1%
BSA and 0.05% Tween 20 (Sigma-Aldrich). TBS (Tris-buffered saline) and TTBS
(TBS with Tween 20) were used in Western blotting. Hoechst 33342 (Invitrogen,
Carlsbad, CA) was used for DNA stains. RBC lysis Buffer (Roche Diagnostics
Corporation) was used in Neutrophil isolation from NSG mice. The near-infrared
lipophilic dye, DiR, and the deep red dye, DiD, were purchased from Invitrogen,
Inc. and PKH26 Red Fluorescent Cell Linker Kit for General Cell Membrane
Labeling from Sigma Aldrich. Chloroform, methanol, and hydrochloric acid were
purchased from Fisher Scientific. N-Biotinyl-NH-(PEG)4-COOH was purchased
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from EMD Chemicals, PEG Biotin, MW 550 was purchased from Nanocs Inc.,
and mPEG-Biotin, MW 5,000 from Laysan Bio Inc.

Blebbistatin (±) was

purchased from EMD Biosciences, and NSC-87877 was from Sigma.

2.4.2 – Antibodies
The fluorescein-labeled antibody B6H12-FITC (BD Biosciences) and
mIAP301-FITC (BD Biosciences) were used against human CD47 and mouse
CD47 respectively. Quantification of SIRPα was performed using anti-SIRPα
(SE7C2) (Santa Cruz Biotech). Human SIRPαex (this laboratory) used for
experiments comparing binding affinities between species. Antibodies against
NMM IIA, actin was obtained from Sigma-Aldrich. Opsonizing antibodies against
mouse RBCs included rabbit anti-mouse RBC (Sigma-Aldrich); Opsonizing
antibodies streptavidin coated polystyrene beads (Spherotech) included rabbit
anti-streptavidin (Sigma-Aldrich), rabbit anti-streptavidin conjugated with FITC
(Rockland Immunochemicals) and Biotin anti-human CD47 Antibody (BioLegend)
were used as IgG opsonin. Secondary antibodies used for detecting opsonin
levels and uningested beads included goat anti-rabbit FITC or goat anti-rabbit
F(ab’)2 R-PE (Sigma-Aldrich). Secondary antibodies used for detecting soluble
SIRPαex or biotinylated CD47 binding included anti-GST Alexa 488 (Invitrogen)
and

Cy5

conjugated

Affinity

Purified

Anti-Biotin

goat

(Rockland

Immunochemicals) respectively. Primary antibody used to measure the level of
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PEG molecules and Biotin anti-human CD47 bounded to streptavidin coated
polystyrene beads was Biotin-4–fluorescein (Anaspec).

2.4.3 – Proteins and Peptides
We followed the protocol described by (Tsai 2008) for the production of
recombinant human CD47 and soluble human SIRPα, proteins were storage at 20˚C in PBS. Human was the focus due to a lack of in vivo experiments on
human-CD47 and known differences with mouse.
In considering synthesis of a ‘Self’-peptide, mouse and human CD47 differ
by about 40% in the sequence that binds SIRPα’s N-terminal domain, and these
differences include one or more amino acids in each of three distinct binding
sequences in the co-crystal.

‘Self’-Peptides were simulated for stability and

interactions and then synthesized by standard solid phase methods in order to
assess whether a synthetic, human-based ligand binds and signals to phagocyte
receptors to passivate the innate immune cells responsible for clearing foreign
objects of many forms. The peptides are:
(1a) 21 aa, >80% purity, Biotin-Acp (N-Terminal) – GNYTCEVTELTREGETIIELK
(1b) 21 aa, >90% purity, Biotin-dPEG4 (N-Terminal) – GNYTCEVTELTREGETIIELK
(2) 12 aa, >80% purity, Biotin-Acp – CEVTELTREGEC (disulfide bridged)
(3) 10 aa, 10 mg, >90% purity, Biotin-dPEG4 (N-Terminal) – EVTELTREGE
(4) 10 aa, 10 mg, >90% purity, Biotin-dPEG4 (N-Terminal) – EGERTLETVE (Scrambled)
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2.4.4 – SIRPα reverse transcriptase PCR and sequence
The SIRPα variant expressed in THP-1 macrophages were confirmed by
RNA extraction (Qiagen) and using a one step reverse transcriptase PCR (RTPCR) amplification (Invitrogen). Samples of the PCR product were run on 1%
agarose gel and gel purified for sequencing. Primers used for both RT-PCR
sequencing include the following 5′-GGGTGAGGAGGAGCTGCAGGTGATT-3′
and 5′-GCGCTCGAGCCGTTCATTAGATCC -3′.

2.4.5 – Plasmid construction and polymorphism mutations
The plasmid vector containing a cytomegalovirus promoter in pEGFP-N1
(Clontech laboratories, Mountain View, CA) containing the DNA fragment
encoding

full

length

human

SIRPα

using

primers

and

GCAGAGCTGGTTTAGTGAACCG-3′

5′5′-

CGTCGCCGTCCAGCTCGACCAG-3′. Full-length human SIRPα variants 1-10 as
denoted (Takenaka 2007) were generated by making point mutants based on
human SIRPα variant 2; using the QuikChange Site-Directed Mutagenesis kit
(Stratagene). For convenience human SIRPα variants 1-10 are denoted as
hSIRPα v1-10. hSIRPα variant 2 to 1 was constructed based on multiple
mutagenesis by using the following primers:
5′-CTGGAGAGACGGCCACTCTGCGCTGCACTGCGACCTCCC-3′ and
5′- GGGAGGTCGCAGTGCAGCGCAGAGTGGCCGTCTCTCCAG-3′
for mutations S54T, I56T, H58R, V61A;
5′-GAGGAGCTGGACCAGGCCGGGAATTAATCTA-3′ and
5′-TAGATTAATTCCCGGCCTGGTCCAGCTCCTC-3′ for mutations A79G;
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5′-CACTTCCCCCGGGTAACAACTGTTTCAGATTTAACAAAGAGAGAAAACA-3′
and
5′-TGTTTTCTCTCTTTGTTAAATCTGAAACAGTTGTTACCCGGGGGAAGTG-3′
for mutations E99D;
5′- ATTCAGCCTGACAAGTCCGTATTAGTTGCAGCTGG-3′ and
5′-CCAGCTGCAACTAATACGGACTTGTCAGGCTGAAT-3′ for mutations S48L;
5′- GTTTCAGATTTAACAAAGAGAAATAACATGGACTTTTCCATCAGG-3′ and
5′-CCTGATGGAAAAGTCCATGTTATTTCTCTTTGTTAAATCTGAAAC-3′
for mutations E104N;
5′-CATGGACTTTTCCATCAGGATCGGTAACATCACCCCAGCAG-3′ and
5′-CTGCTGGGGTGATGTTACCGATCCTGATGGAAAAGTCCATG-3′
for mutations S111R, S113G;
5′-GGAAAGGGAGCCCTGACGTGGAGTTTAAGTCTGGAG-3′ and
5′-CTCCAGACTTAAACTCCACGTCAGGGCTCCCTTTCC-3′ for mutations
T135V;
5′-GAAAGGGAGCCCTGACGACGTGGAGTTTAAGTCTGG-3′ and
5′-CCAGACTTAAACTCCACGTCGTCAGGGCTCCCTTTC-3′ for inserting D at
135.
hSIRPα variant 2 to 3 was constructed with the primers
5′- GTCGGCCATTCTGCTCTGCACTGTGACCT-3′ and
5′- AGGTCACAGTGCAGAGCAGAATGGCCGAC-3′ for mutations H58L.
hSIRPα variant 2 to 4 was constructed using primers:
5′-GCGGGTGAGGAGGGGCTGCAGGTGATT-3′ and
5′- AATCACCTGCAGCCCCTCCTCACCCGC-3′ for mutations E37G;
5′-TCTGCACTGCACTGCGACCTCCCTGATCC-3′ and
5′- GGATCAGGGAGGTCGCAGTGCAGTGCAGA-3′ for mutations V61A.
hSIRPα variant 2 to 7 was constructed using the following primers:
5′- CTGTCTGTGCGTGGCAAACCCTCTGCC-3′ and
5′- GGCAGAGGGTTTGCCACGCACAGACAG-3′ for mutations A149G.
hSIRPα variant 2 to 10 was constructed using primers
5′- TGCGCCTGGTCAAGAGTGGCGGGTG-3′ and
5′-CACCCGCCACTCTTGACCAGGCGCA-3′ for mutations G31R.
hSIRPα variant 1 to 5 was constructed using primers
5′- GGTGATTCAGCCTGACAAGTTCGTATTAGTTGCAG-3′ and
5′- CTGCAACTAATACGAACTTGTCAGGCTGAATCACC-3′ for mutations S46F.
hSIRPα variant 1 to 6 was constructed using primers:
5′- AGATTTAACAAAGAGAAATAACATGGACTTTCCCATCAGGATCGGTAA-3′
and
5′- TTACCGATCCTGATGGGAAAGTCCATGTTATTTCTCTTTGTTAAATCT-3′
for mutations S109P.
hSIRPα variant 1 to 9 was constructed using primers
5′- ACTTTTCCATCAGGATCAGTAACATCACCCCAGCA-3′ and
5′-TGCTGGGGTGATGTTACTGATCCTGATGGAAAAGT-3′.
All constructs were confirmed by sequencing.
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2.4.6 – Cells culture and transfection
COS-1, CHO-K1, A549, THP-1 cells (American Type Culture Collection)
were respectively maintained in DMEM, MEMα, F-12, RPMI 1640, and DMEM
low glucose media (Invitrogen) supplemented with 10% heat inactivated FBS
(Sigma-Aldrich). Cells were detached using 0.25% Trypsin/0.5mM EDTA
(Invitrogen) for passaging. Differentiation of THP-1 cells was achieved in 100
ng/mL phorbol myristate acetate (PMA) (Sigma-Aldrich) for 2 days and confirmed
by attachment of these cells to tissue-culture plastic. Peripheral blood monocytes
from human donors were obtained through the Human Immunology Core
(University of Pennsylvania). Human blood was obtained from finger pricks of
healthy donors. Blood from other species was obtained from Covance and
washed 3x in PBS plus 0.4% BSA.
hSIRPα v1-10 was transfected into CHO-K1 cells with Lipofectamine 2000
(Invitrogen) according to manufacturer’s instructions. Clones resistant to 400
µg/ml G418 (Invitrogen) were selected. Expression of hSIRPα was confirmed.
Transfected cells were harvested using DPBS supplemented with 2 mM EDTA
(Invitrogen) 1-2 days post-transfection for analysis. In addition to detection for
GFP signals, anti-SIRPα (Santa Cruz Biotech) was used to confirm surface
expression by fluorescent microscopy and flow cytometry.
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2.4.7 – Preparation and characterizations of Nanobeads with CD47, ‘Self’
peptide, and Opsonin
Beads enable facile addition of ‘Marker of Self’ ligands, but rigid beads
must be far smaller than highly flexible RBC to avoid first-pass clearance from
the microcirculation (Deplaine 2010). Nanoparticles are thus needed but if they
are too small, then they can be a challenge to controllably modify and fully
characterize after injection.
Streptavidin-coated polystyrene beads of 160 nm radius (SVP-03-10;
Spherotech, Lake Forest, IL) were washed and blocked 3x in PBS plus 0.4%
BSA. Manufacturer specifications of about 3x104 Biotin–fluorescein sites per
nanobead were confirmed by flow cytometry with fluorescence calibration beads
and equate to about 1 biotin site per 10 sq.nm (Fig. S2A). This is the maximum
density of modification (eg. PEGylation) achievable with these nanobeads, and
compares well with useful densities in related contexts. Malmsten et al. reported
95% suppression of protein adsorption (at a specified time point) for PEG
surfaces with 1 polymer per 10 sq.nm although protein adsorption was still
measurable. In addition, with liposomes the area per lipid is 0.7 sq.nm, and
PEGylated liposomes exhibit ‘stealth’ in circulation with 2-5% PEGylation (eg.
Photos2003), which equates to one PEG chain per 14 - 35 sq.nm.
Recombinant biotinylated hCD47 or synthetic biotinylated ‘Self’-peptide
were attached to the beads and then rabbit anti-Streptavidin conjugated with
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FITC was added as an opsonizing IgG-antibody (Rockland Immunochemicals).
Beads were incubated at room temperature for 30 min, washed 3x, and resuspended in PBS plus 0.4% BSA. The density of hCD47or ‘Self’ on the beads
was determined by binding to soluble hSIRPα at 1 µM (see Binding Isotherms
below) and, for hCD47, labeling with 15 µl of anti-hCD47-FITC (clone B6H12, BD
Biosciences).

Binding of hSIRPα was thus used to confirm similar levels of

attachment of hCD47or ‘Self’ on the beads (see Fig. 3A). The opsonin density
on the beads was determined with 1 µl goat anti-rabbit F(ab’)2 R-PE incubated
for 30 min at room temperature. Beads were washed and resuspended in PBS
for flow cytometry and further analyses.
Zeta potential measurements (Malvern Zetasizer) on key samples
of Fig. 1C showed no significant differences: for (anti-streptavidin nanobeads),
(hCD47 + anti-streptavidin nanobeads), (‘Self’-peptide + anti-streptavidin
nanobeads), (Scrambled peptide + anti-streptavidin nanobeads) all had a
measured Zeta potential = -3.5 ± 1 mV. Sizes from light scattering for these
nanobeads as well as PEGylated nanobeads conformed to manufacturer’s
specifications within about 10%. Forward and Side scatter in flow cytometry from
pre-injected nanobeads provided additional evidence of uniformity of size even
after the modifications.
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2.4.8 – Binding isotherm for soluble hSIRPα for hCD47 and Polypeptides
The binding isotherm of soluble hSIRPα was performed for Polypeptides
and hCD47 attached to the streptavidin polystyrene beads as noted over a range
of concentration using flow cytometry. Forward scatter, side scatter and
fluorescence (FL1, FL2, FL3, FL4 channels in logarithmic mode) were acquired
for at least 104 events using a FACScan or FACSCalibur (BD Immunocytometry
Systems). Data points from flow cytometry were plotted and fitted to obtain the
Kd values as shown.

2.4.9 – Phagocytosis Assay
For phagocytosis assays, macrophages were plated in 4cm2 Lab-Tek II
Chambered Coverglass (Nalge Nunc International) at 1 x 105/4cm2. Streptavidin
polystyrene beads were added to macrophages at a number ratio of 20:1 and
allowed to incubate at 37˚C for 45 min. Non-phagocytosed beads were washed
with PBS. Cells were fixed with 5% formaldehyde (Fischer Scientific) for 5 min,
followed by immediate replacement with PBS. For differentiation of noninternalized beads, beads were labeled with a primary antibody, rabbit antistreptavidin (Sigma) at 1:1,000 in PBS for 20 min at 25°C. A second antibody,
anti-rabbit R-PE (Sigma) was added at 1:1,000 in PBS to the cells and incubated
for an additional 20 min at 25°C. Cells were then w ashed with PBS/ 0.4% BSA
and then quantified by light and fluorescent microscopy. At least 200 cells were
scored per well and experiments were repeated at least three times.
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For stimulated phagocytosis assays, beads with or without Polypeptide,
PEG or CD47 were incubated with rabbit anti-streptavidin as the opsonin. Beads
were opsonized at the respective concentration for 30 min at RT. Opsonized
beads were washed 2x and resuspended in 50 µl of PBS/0.4% BSA. Phagocytes
were washed with PBS beads were labeled as described above.
For cytoskeletal involvement at the phagocytic synapse, streptavidin
beads opsonized with rabbit anti-streptavidin FITC. Opsonized beads of different
sizes were added to PMA treated THP-1 cells and immediately placed at 4°C for
10 min to synchronize phagocytosis. The temperature of the cells was then
immediately increased to 37°C for 10 min and then f ixed with 5% formaldehyde
for immunofluorescence. For studies involving blebbistatin (EMD Biosciences),
macrophages were treated for 10 min at 4ºC prior to temperature increase to
37ºC or for 45 min. Macrophages treated with DMSO were used to verify no
solvent effects.
Images were acquired with an inverted microscope (Olympus; IX71) with a
60x and 150x (oil, 1.4 NA) objective using a Cascade CCD camera
(Photometrics, Tuscon, AZ). Image acquisition was performed with Image Pro
software (Media Cybernetics, Silver Spring, MD). All subsequent image analysis
was done using ImageJ.
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2.4.10 – SHP-1 inhibitor effect on phagocytosis
PMA activated THP-1 macrophage was treated with a SHP-1 inhibitor
(NSC-87877) provided by Dr. Frank L. Conlon (University of North Carolina) from
0-100 nM in DI water for 5 min prior to the addition of IgG-opsonized particles.
Phagocytosis assay of IgG-opsonized particles coated with or without CD47 at
100 nm and 1.1 µm radius were conducted as described above.

2.4.11 – Inhibition of nanoparticle uptake
THP-1 macrophages activated with PMA were incubated with 10 µg/ml
chlorpromazine in distilled water or 30 µM cytochalasin B in DMSO (SigmaAldrich) for 30 min at 37°C. Control cells were inc ubated with the medium with
solvent. Followed by incubation with the above inhibitors, THP-1 cells were used
for uptake studies with or without IgG-opsonized 100 nm radius particles targets
as described above.

2.4.12 – Immunofluorescence microscopy
Immunostaining was performed after cells were fixed and blocked for 1 h
with 5% BSA in PBS. Staining with primary antibody anti-rabbit PE-conjugated
(1:200) was used for detection of non-phagocytosed beads for 1 h at room
temperature in PBS. After washing, samples were fixed with 5% formaldehyde
and imaged. In order to ensure that the cells were not permeable to labeling an
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antibody against myosin IIA was used to confirm not labeling occurred (SigmaAldrich).
Images were acquired on an inverted microscope (IX71; Olympus) with a
40x or a 60× (oil, 1.4 NA) objective using a Cascade CCD camera
(Photometrics). Image acquisition was performed with Image Pro software
(Media Cybernetics, Inc.). All subsequent image analysis was done using
ImageJ.

2.4.13 – Immunoprecipitation and Western blotting
Human Phagocytes, THP-1 wild-type (2x106) were cultured and
differentiated in 6-well plates for 48 hours after PMA differentiation. Human
CD47, PEG and Polypeptides were attached to 2.1µm diameter beads at specific
densities as described above and added at a bead to cell ratio of 20:1 for 10
minutes. Following the incubation time, the cells were washed with ice-cold PBS
and then lysed on ice in 300 µl of lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 1mM EDTA, 1% NP-40, 1% protease inhibitor cocktail [Sigma-Aldrich] and
2mM activated sodium orthovanadate). For immunoprecipitation, whole lysate
was mixed with 1:200 anti-SIRPα (SE7C2) antibody (Santa Cruz Biotechnology,
Inc.) with Protein G agarose (Pierce) at 4˚C overnight. Precipitated proteins was
placed in 4-12% SDS-PAGE in MOPS buffer (Invitrogen), transferred to PVDF
membrane, blocked and labeled via phosphotryosine IgG HRP-conjugated (Cell
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Signaling) and anti-SIRPα (C-20) (Santa Cruz Biotechnology, Inc.) as primary
antibodies and anti-goat-HRP (Amersham). All Westerns were run in duplicate,
along with an additional blot for actin to ensure constant protein load among
samples.

2.4.14 – Biodistribution Study with dye-labeled Beads
All mice were treated in accordance with approved IACUC protocols at the
University of Pennsylvania. Near Infrared Fluorophore (NIRF)-labeled and
unlabeled streptavidin coated polystyrene beads were injected into the tail veins
of healthy Adult Immune-deficient (NSG) Mice (4-8 weeks).

The range of

injected beads was ~107 per ml, with some variability due to accuracy of locating
the tail vein. Every 10 min, 5 µl blood samples were collected by retro-orbital
bleeding. At 35min following injection, mice were sacrificed and whole blood,
liver, spleen, lungs, kidneys, heart and brain were collected. The whole blood
was then centrifuged and plasma collected.
Organs were imaged on the LiCor Odyssey imaging system (LI-COR
Biosciences, Lincoln, NE) at 800 nm excitation. The integrated fluorescence
intensity of the organs was normalized using the organ correction factor found by
Christian et. al. (Christian 2009) and applied to all other measured intensities for
all organs. The NIR intensity of the plasma was measured on the LiCor and
calculated by fitting the slope of the linear dilution curve.
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2.4.15 – Preparation of erythrocytes for injection
Blood from NSG mice were acquired by Cardiac Puncture, erythrocytes
were separated from the rest of the blood component by centrifugation gradient
to isolate the RBC pellet package. Samples were divided into two groups, they
were labeled with a hydrophobic dye DiD and PKH 26 respectively and incubate
for 20 min at room temperature (RT). Both samples were washed with PBS/
0.4% BSA and then one of them was incubated with anti-mCD47 (mIAP) primary
antibody for 45 minutes and both of them were opsonized with excess rabbit antimRBC prior to mixing cells together and injecting into the tail vein for 30 min at
room temperature (RT). Cells were then washed with PBS/ 0.4% BSA and one
quantified by light and fluorescent microscopy

2.4.16 – Measuring Beads and RBC in circulation
The total numbers of beads remaining in circulation were measured using
flow cytometry with 10ul the samples collected from each mouse.
Beads, in whole blood sample (or serum), were labeled with 15µl of
B6H12-FITC (BD Biosciences) against human-CD47 and with 1µl goat anti-rabbit
F(ab’)2 R-PE against rabbit anti-streptavidin (Sigma-Aldrich) for 30 min at room
temperature. Beads were washed and resuspended in PBS for flow cytometry
analysis.
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Forward scatter, side scatter and fluorescence (FL1, FL2, FL3, FL4
channels in logarithmic mode) were acquired using a FACScan or FACSCalibur
(BD Immunocytometry Systems). Data points from flow cytometry were plotted
and the total number of beads in each 10ul sample was counted by the total
number of events with the appropriately distinct forward and side scatter. These
events also appeared positive for Opsonization and human-CD47.

2.4.17 – In vivo Blocking mouse-SIRPα
We pre-inject 4 NSG mice (30-120min and 24 hour before particle
injections) with 100ug of CD172a (BD Biosciences) antibody. hCD47
nanoparticles were injected to each of the pre-injected mice and to 1 not preinjected (control). At 35min following injection, mice were sacrificed and whole
blood and spleen were collected.
The circulating particle ratio at 35 min was measured using flow
cytometry. Forward scatter, side scatter and fluorescence (FL1, FL2, FL3, FL4
channels in logarithmic mode) were acquired using a FACScan or FACSCalibur
(BD Immunocytometry Systems).

2.4.18 – Collagenase Digestion.
Spleens were chopped into pieces and placed into tubes containing 1 ml
of collagenase/DNase solution [1 mg/ml type II collagenase (Worthington
Biochemicals) and 0.1% DNase I (Sigma) in RPMI medium 1640 plus 10% FBS].
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The suspension was pipetted intermittently for 20-30 min at 37°C. Cells were
then washed, treated to remove red blood cells, and counted before staining for
flow cytometry to immunostain for macrophages with F4/80 (Bioscience, Inc.).
Forward scatter, side scatter and fluorescence (FL1, FL2, FL3, FL4
channels in logarithmic mode) were acquired using a FACScan or FACSCalibur
(BD Immunocytometry Systems).
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peptide and human-CD47
CD47 prolong the circulation of
Fig. 2.1.- “self”-peptide
nanobeads in NSG mice.
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(A)
Competitive circulation experiment in which two colors of nanobeads or
cells are mixed and injected into the same mouse after labeling with either red
(PKH26) or a far-red (DiD) fluorophores. 50 µl of blood was periodically
sampled, and flow cytometry analysis of decays in particle numbers are used to
calculate the time-dependent persistence ratio in each mouse. (B) Circulation
experiment in which mouse-RBC (mRBC) from NSG mice were CD47-blocked or
not and also opsonized with excess anti-mRBC prior to mixing cells together and
injecting into the tail vein (n = 3 mice; R2 = 0.93 for fit of means with indicated T).
(C) Upper sketch: nanobeads in blood flow being cleared by a splenic
macrophage (left) or else recognized as “self” and let go (right). Circulation
experiments used 160 nm polystyrene beads with covalently attached
streptavidin incubated with biotinylated versions of: synthetic ‘Self’ peptide (n =
4; R2 = 0.94 for fit of means), recombinant hCD47 (n = 6; R2 = 0.92 for fit of
means), or negative controls of either scrambled peptide (n = 3) or PEG (n = 5).
Nanobeads were also opsonized with anti-streptavidin and then 107 were
injected. Flow cytometry quantitation was typically done on 100-10,000 particles
at each time point, and typically included quantitation of both hCD47 and opsonin
on the nanobeads. For hCD47 and ‘Self’ peptide, a separate fit for each mouse
gives the indicated mean T ± SEM for each group, which is within 10% of the T
obtained from fitting the group averages (dashed curves). Based on these
analyses, an apparent difference between hCD47 and ‘Self’ peptide is not
significant (p = 0.18), but nearly all datapoints do differ from PEG-nanobeads (* p
< 0.05). All data are mean ±SEM.
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Fig. 2.2.- Persistence of hCD47- and “self”- nanobeads depends on hCD47
density, consistent with low affinity binding to NSG-mouse SIRPα relative
to human-SIRPα variants.
(A) The number of hCD47 molecules on the 160 nm beads at 35 min after
injection was either measured in two color experiments (solid; n = 7 mice) or
single color experiments (open; n = 6 mice), with an average of 30% protein lost
in circulation (inset). ‘Self’ peptide levels are estimated to have a similar loss (n =
4 mice). Fluorescent nanobeads (PKH26+ in flow cytometry, upper plots) were
confirmed by forward/side scatter, and fluorescent anti-hCD47 measured hCD47
levels (left plot is control nanobead sample, and right plot is hCD47 nanobead
sample). The inhibition curve gives Ki = 110 molecules/nanobead. (B) Affinity
of soluble hCD47 for fresh NSG neutrophils and monocytes, using flow cytometry
analysis of Cy5-anti-Biotin. Lymphocytes are negative for SIRPα and do not bind
soluble hCD47. In inset we show a blocking experiment for mSIRPα using antimouse SIRPα antibodies that block binding of mouse-SIRPα to hCD47. We preinject the antibody into 4 mice (30-120min before) and we didn’t inject antibody in
one of the mice. The circulating particle ratio at 35 min was measured and we
also broke up the spleen and used flow cytometry to immunostain for
macrophages with F4/80. (C)Ten reported variants of hSIRPα’s N-terminal
domain (Takenaka2007) were displayed on CHO cells to determine affinities for
soluble hCD47 (Fig. 2.S4). The putative allele frequency is plotted versus the
measured affinities, with the highest frequency at intermediate affinity. On this
scale, the affinity of hCD47 for mSIRPα on NSG phagocytes (blue square)
proves weak while the affinity of “self”-peptide for hSIRPα is strong (green
diamond). The Lorentzian fit is inspired by other mechanobiological signaling
processes and has the form: y = 1+ 0.05x11/(0.5011 + x11)2, R2 = 0.85. (D) The
co-crystal structure of hCD47 and hSIRPα (Hatherley 2008) identified the FG
loop in hCD47 as one of two interaction sites, and so it formed the basis for
design and simulation of several polypeptides (details, Fig. 2.S5). The upper right
plot shows loop dimensions versus time in solution for hCD47, for the “self”peptide, and for the disulfide containing “self”-SS-peptide, which tends to be
larger (regime c). The lower histograms show the frequency of salt bridges
formed between these two peptides and hSIRPα when docking various
configurations from the size ranges a-c. (E) Affinities of peptides on beads for
soluble hSIRPα based on flow cytometry measurements of beads (see Methods).
Fits to saturation binding gave the indicated dissociation constants, Kd. Neither
the “self”-SS-peptide nor the Scrambled-peptide exhibit any affinity for hSIRPα.
The assays in (iii) use soluble versions of the peptides, lacking biotin, and show
the unstructured “self”-hairpin is a weak inhibitor of the interaction. Bargraph
insets in (i,ii) show in vitro phagocytosis assay results with the human THP1 cell
line (see Methods), demonstrating that only the “self”-peptide (with C6 or PEG
linkers) significantly inhibits phagocytic uptake (p < 0.05).
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Fig. 2.3.- Phagocytosis of nanobeads is efficient and recruits Myosin-II,
unless CD47 or “self”-peptide bind SIRPα and signal inhibition through
SHP1.
(A) Nanobead uptake in vivo in NSG mice and in vitro with human-derived THP1
macrophages. (i) Splenic macrophages co-localize with nanoparticles in situ.
Spleens harvested at 35-40 min were frozen-sectioned, fixed and permeabilized
for immunostaining green for macrophages (MΦ) and red with a secondary
antibody against anti-streptavidin opsonized beads (goat anti-rabbit F(ab’)2).
Nuclei are stained blue with Hoechst dye. (ii) Phagocytosis of fluorescent 100 nm
beads (red) by THP1 cells in vitro was assessed at 45 min by immunostaining
cultures that were fixed (but not cell permeabilized) for non-ingested beads using
secondary antibody against anti-streptavidin. Nonmuscle Myosin-IIA (a, lower
panel) enriches near the nanoparticle unless hCD47 is on the bead (b, plot).
Myosin-II’s enrichment near the nanobead extends deeply into the cytoplasm (~5
µm) relative to bead size, suggestive of a diffuse signal that directs cytoskeletal
assembly. Nanobeads with anti-streptavidin are readily engulfed at about 1 bead
per cell (c), but uptake is inhibited by hCD47 and by inhibition of Myosin-IIA with
blebbistatin (50 µM). Inhibition of SHP1, downstream of SIRPα, with NSC-87877
blocks the inhibition of uptake by hCD47. DMSO is the solvent for the drugs. (B)
Phosphorylation of hSIRPα tyrosines in THP1 cells upon contact with opsonized
nanobeads bearing hCD47 and ‘Self’ peptide. hSIRPα was immunoprecipitated
from cell lysates and phosphotyrosine was immunoblotted for quantitation (n = 3;
*p < 0.05). (C) Inverse correlation between in vivo persistence ratio at 35 min
and in vitro inhibition of phagocytosis by hCD47 and ‘Self’ peptide at 45 min for
160 nm beads. All data are mean ±SEM.
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Fig. 2.4.- Phagocytic activation can be passivated almost independent of
curvature through signaling by hCD47 and a minimal “self”-peptide
designed from the binding site with SIRP
SIRPα.
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Fig.2.S1.- Two-color RBC show for each color that mouse-CD47 prolongs
Circulation, and Single Color Nanobeads show hCD47 and “self”-peptide
prolong Circulation.
(A) Representative images of blood samples taken at 10 min after injection of
NSG mouse-RBC (mRBC) treated with anti-CD47 antibody (blue) or unblocked
control mRBC (green). The opsonization level of the RBC was measured for
each condition before injection, which showed approximately 2000
molecules/um2 for both samples. (B) Two-color RBC experiment shows that
mouse-CD47 prolongs circulation independent of fluorescence labeling. 50 µl of
blood was periodically sampled, and flow cytometry analysis of the decays in
particle numbers were used to calculate the circulation kinetics for each condition
in each mouse. A doubling time similar to that in Fig.2.1B can be estimated from
these results, and if it were extrapolated to one full day would yield 224h/33min (~10trillion) more RBC with CD47 compared to every circulating RBC without CD47.
This exceeds by ~100-fold the daily production of RBCs in humans and begins to
suggest the potency of CD47 and/or co-factors on RBC. (C) Nanobeads in
whole blood samples were identified using a unique methodology in flow
cytometry for nanobeads in circulation . Forward and side scatter were used to
separate nanoparticles from the rest of the blood components as well as by using
anti-streptavidin antibody and the appropriate isotype controls (histograms) (D)
Single Color Nanobeads show hCD47 and “self”-peptide prolong circulation. 50
µl of blood was periodically sampled from mice injected with one type of
functionalized bead (hCD47, “self” peptide, or IgG control), and the circulation
kinetics of the beads was measured by flow cytometry. Bare 320nm beads were
cleared in vivo slower than IgG-opsonized but faster than beads functionalized
with Opsonin+hCD47 and Opsonin+”self” peptide. (E) Any Targeting antibody will
also opsonize nanoparticles and promote in vivo clearance. Since CD47 has
been therapeutically targeted with antibodies, we attached biotinylated-(antihCD47) (see Methods) to the nanobeads and co-injected in mice with beads
having anti-streptavidin (n = 3 mice). Periodic bleeds were analyzed by flow
cytometry with quantitation of 100-1000 particles and verification of antibody
attachment to the nanobeads. Beads are cleared equally for both antibodies.
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Fig.2.S2.- IgG gives rapid clearance, while PEG (no IgG) gives long
circulation and PEG + CD47 is better.
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(A) Single Color Nanobeads show PEG beads and hCD47-PEG beads prolong
circulation. 50 µl of blood was periodically sampled from mice injected with one
type of functionalized bead (hCD47 or IgG control), and the circulation kinetics of
the beads was measured by flow cytometry. PEG 320nm beads were cleared in
vivo slower than IgG-opsonized Beads but faster than beads functionalized with
PEG+hCD47. (B) Circulation experiments used 160 nm polystyrene beads with
covalently attached streptavidin (Spherotech) incubated with biotinylated
versions of: PEG MER (n = 1), PEG 0.5K (n = 2), PEG 5K (n = 1). Beads were
also opsonized with anti-streptavidin and then ~107 were injected. Flow
cytometry quantitation was done on 100-1000 particles at 35min time point.
Error bars are SEM; Characterization of beads size and surface charge were
made with DLS and they didn’t show any significant different between the
particles. (C) Flow results for PEG molecules attached to nanobeads in vitro.
Numbers of Fluorescein-Biotin molecules on the 160 nm beads were measured
by flow cytometry at different concentration of Biotin-PEG attached to the beads
first. The color arrows point to the max density used in vivo for each PEG size.
(D) Phagocytosis in vitro for PEG-Beads. in vitro inhibition of phagocytosis by
hCD47 at 45 min for 160 nm Pegylated beads.
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Fig.2.S3.- Human and Mouse CD47 inhibit Splenic clearance based on
imaging the Spleen and Tumor imaging is enhanced after second injection
of hCD47-Nanobeads.
Nanobeads.
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(A) Human CD47 inhibits splenic clearance of highly opsonized (6000
molecules/µm2) nanobeads in NSG mice. Accumulation of NIR-labeled
nanobeads in the spleen was determined by total splenic NIR fluorescence
intensity as measured by an Odyssey imaging system (LI-COR Biosciences) (B)
Flow cytometry data shows binding of soluble mouse-SIRPα-GST to recombinant
mouse CD47 attached to particles and also to nanoparticles with blocked
mouseCD47 (mIAP301). Beads in circulation were collected 30 and 60 minutes
after injection, and the concentration of beads opsonized with anti-streptavidin
was compared to opsonized beads also coated with biotinylated mouse CD47.
Spleens were harvested at 60 min after injection (n=3) and the number of
particles were measured by splenic NIR fluorescence intensity (C) At 40 min
post-injection of two colors of nanobeads, mice were sacrificed and whole blood,
liver, spleen, lungs, kidneys, heart and brain were collected. NIR fluorescence
intensity of each organ was measured and normalized for organ weight and
optical density as well as for NIR signal resulting from particles in the blood
volume of each organ. The NIR fluorescence intensity of the plasma was
calculated by serial dilution in PBS. Plot showed results for n = 6 animals per
group of control 160 nm polystyrene opsonized beads (blue bar) and similar
beads functionalized with biotinylated hCD47 (red bar). All error bars are SEM,
and (*) indicates p < 0.05. For Scrambled-peptide, measurements were more
limited but clearly show rapid clearance from blood. (D) Normalized NIR
fluorescence intensity for all organs in tumor-bearing mice measured by the
Odyssey imaging system (n=2).
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Fig.2.S4.- CD47 is progressively lost from Nanobeads in circulation, and
Nanobead Numbers at early times do not correlate with Bead Ratios at
endpoint.
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(A) Increased surface density of hCD47 on the Nanobeads enhances the number
of Nanobeads in circulation in single color bead experiments. Circulating Beads
Numbers are proportional to the hCD47 concentration found on the surfaces of
the beads measured by flow cytometry. Blood samples were taken at 10, 21 and
35min after single color beads injections. (B) In two color bead experiments, the
number of beads at early timepoints does not correlate with the ratio at 35 min.
In other words, PEG and Scrambled peptide fail to enhance persistence in
circulation over a broad range of particle numbers, while ‘Self’ and hCD47 do
work over a broad range of particle numbers but otherwise show no trend.
These results suggest that the macrophages are not saturated by the beads in
these experiments; if the macrophages were saturated, then the likely trend
would be a decay in hCD47 beads toward a ratio of 1 because control beads
would no longer be cleared. Dashed lines indicates means.
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Fig.2.S5.- hSIRPα variants exhibit di
different
fferent affinities for hCD47.
hCD47
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(A) GFP-tagged full-length human SIRPα GFP (hSIRPα-GFP) was confirmed to
be transiently expressed in CHO-K1 cells by GFP expression, and surface
expression was confirmed with anti-SIRPα antibody by flow cytometry. (B)
Affinities of surface-expressed hSIRPα variant 10 for soluble hCD47 was
measured by flow cytometry. Saturation binding fits gave the indicated
dissociation constants, Kd. (C) Human SIRPα polymorphisms variants 1-9
expressed on CHO cells with affinity binding to soluble hCD47 was based on flow
cytometry. Saturation binding fits yield the dissociation constant, Kd was
summarized in the plot with binding curves repeated in triplicate ± standard
deviation. (D) The binding affinity of hCD47 bound to the surface of beads to
hSIRPα was measured using varying concentrations of soluble hSIRPα v10 to
determine the dissociation constant, Kd. (E) Linear relationship between the Kd
obtained for surface-expressed hSIRPα polymorphisms variants 2,7 and 10 and
soluble hCD47 and Kd obtained for hCD47 attached to beads and soluble
hSIRPα variants.
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Fig.2.S6.- Molecular Dynamics Simulations of Structures reveal Folding and
Interactions.
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(A) Full atomistic molecular dynamics (MD) simulations were performed for over
50 ns with the hCD47-hSIRPα complex (PDB: 2JJS), with each component in
water at the indicated solution conditions in constant particle isothermal-isobaric
ensemble (NPT) constraints. Systems were equilibrated for over 5 ns followed
by production runs for structural analysis. (B) The “self”-peptide has interstrand
hydrogen bonds that increase the stability of the hairpin, while the “self”-SSpeptide has a mutation at T107C that promotes a disulfide bridge with C96 and
induces a torque and splay in the circularized peptide. Both peptide structures
are stable since unstable configurations tend to rearrange within 10 ns (Ivetac
2008). For electrostatic calculations of Fig. 2.3D we used Adaptive PoissonBoltzmann Solver (APBS) (Baker 2001) as implemented in VMD (Humphrey
1996). (C) Peptide complexes with hSIRPα were obtained via computational
docking. Structural heterogeneity of the peptide was taken into account by
sampling of 100 representative configurations from a 100 ns long MD trajectory.
Docking was performed using HADDOCK (Dominguez 2003), an algorithm able
to bias the stochastic exploration of the configurational space via aptly defined
distance restraints between sets of residues from the two complex constituents.
The configurational space of the complex was sampled via a three-stage
protocol: (i) Randomization of orientations and rigid body energy minimization; (ii)
Semi-flexible simulated annealing in torsion angle space; (iii) Final refinement by
MD simulations in Cartesian space with explicit solvent. For each conformation of
the peptide, 2,000 structures of the complex were generated, and from these the
best 200 were employed for further analysis. Salt bridges of Fig. 2.3E were
calculated by identifying pairs of negatively and positively charged atoms within 4
Å, (Barlow 1983) without accounting for relative orientation.
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Fig.2.S7.- The role of particle size, Myosin IIA, and SHP-1 in particle
phagocytosis by macrophages
(A) Nano to micron sized IgG-opsonized particles can be observed in phase
contrast images (top) and fluorescent microscopy (bottom) to determine
phagocytosed (green) versus non-phagocytosed particles (yellow) (see materials
and methods). The number of IgG-opsonized particles per phagocyte was plotted
for 160 nm and 1.1 µm at either a constant particle surface area or constant
particle number, with 200 phagocytes counted (n=3, ± SD). (B) In the presences
of bacteria, THP-1 phagocytes expressing (i) wild-type GFP-Myosin IIA (MYH9)
show localization with arrows indicating points of contact in phase contrast and
GFP image insets. (ii) A tyrosine mutation of GFP-MYH9 results in non-functional
MyH9 and thus no GFP localization in the presence of bacteria. (iii) In THP-1
macrophages expressing wild-type GFP-MYH9, GFP signal localizes around 1.1
µm particles alone. (iν) hCD47 attached to the particle surface inhibits GFPMYH9 localization around the particles (ν) Larger 3.4 µm particles show GFPMYH9 localization (inset). Scale bar 10 µm (vi) hRBC provide a hCD47 control
for GFP-MYH9 localization in THP-1 cells. (C) Streptavidin beads were coated
with varying concentrations of biotinylated hCD47 and anti-streptavidin IgG as
the opsonin. Inhibition of phagocytosis is dependent on the density of human
CD47 on beads but independent of particle sizes ranging from 100 nm to 3.5 µm.
Phagocytosis inhibition occurs with an effective Ki ≈ 20 molecules/µm2 for
particles from micro to nano-meter beads. The vertical blue bar is the normal
density of CD47 found on normal human RBC (~250 CD47/µm2) and the
horizontal gray bar indicates the level of phagocytosis of unopsonized beads. (D)
IgG-opsonized particles of radius 100 nm or 1.0 µm with or without hCD47 on the
surface were incubated with THP-1 macrophages with an SHP-1 Inhibitor (NSC87877) at 62.5 nM. The effects of SHP-1 inhibition were determined by the ratio
of ingested particles per THP-1 phagocyte (see Materials and Methods). The
numbers of particles ingested are shown based on 200 phagocytes counted (n ≥
3, ± SD). Inset shows the concentration dependence of NSC-87877 effect on
particle uptake.
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CHAPTER 3 - Synthetic “self” peptide or hCD47 recombinant
protein can enhance the effect of an anti-cancer drug
Pia L. Rodriguez, Takamasa Harada, Anthony Secreto and Dennis E.
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T. Harada helped with Imaging and Taxol loading studies and he also helped
with the generation of the A549 tumors cells. A. Secreto helped with the mice
injections, organs harvesting, mouse weight and tumor size measurements.
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Abstract

Anti-phagocytic signals mediated by CD47–SIRPα interactions on cancer
cells enable them to “hide” from innate immune system surveillance. CD47 is a
critical regulator of innate immune surveillance, and is found in increased levels
in various tumors. Monoclonal antibodies targeted to CD47 have been shown to
lead to phagocytosis of cultured solid tumor cells in vitro and to prevent the
metastasis of human tumor cells. Here, recombinant hCD47 or synthetic “self”peptide was attached to virus-size nanoparticles for injection into NOD.SCID

(NSG) mice-- which are known to exhibit unique compatibility with human cells—
resulting in enhanced imaging of tumors with Near-Infrared nanobeads,
increased tumor perfusion of the particles and a subsequent EPR effect. This
indicates that the beads might be able to evade the immune system and thus be
of potential biomedical application. The “self”-beads and hCD47-beads enhanced
near-infrared imaging of human tumor xenografts by over tenfold. The hCD47
beads also led to statistically significant tumor shrinkage similar to that observed
with beads carrying Cremophor® EL-paclitaxel (Taxol) treatments, but without
the noted toxicity of Cremophor® EL. We successfully targeted human cancer
cells with antibodies against CD47, where the “self”-peptide blocked phagocytic
clearance from circulation and suppressed tumor growth within one day after
injection. The antibody targeting approach revealed the importance and utility as
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well as limitations of a human ‘Marker of “self”’ to improve drug delivery when
bound to nanobeads along with a bioactive antibody against a therapeutic target.

3.1 – Introduction

The concept of tumor immune surveillance-- the identification and
elimination of cancer cells by the immune system-- was first discussed over a
century ago, and since then multiple immune system components have been
implicated (Swann 2007). However, the role of macrophage phagocytosis in
tumor pathogenesis has been relatively unexplored. Recent studies have
demonstrated that tumors evade macrophage phagocytosis through the
expression of anti-phagocytic signals, especially the ones mediated by
antagonists of the CD47–SIRPα interaction against cancer cells (Chao 2011,
Zhao 2011). CD47 is a critical regulator of innate immune surveillance in that
monoclonal antibodies targeted to CD47 enable the phagocytosis of solid tumor
cells in vitro and prevents the metastasis of human tumor cells (Willingham,
2012).
The increased expression of CD47 on many different human tumor types
enables tumors to escape innate immune system surveillance through evasion of
phagocytosis. This process occurs through binding of CD47 on tumor cells to
SIRPα on phagocytes, thus promoting inhibition of phagocytosis and tumor
survival (Chao 2012) and suggests the potential for targeting the CD47–SIRPα
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pathway as a common therapy for human malignancies. CD47 on nanoparticles
should likewise limit uptake by tumor-associated macrophages of nano-particle
imaging agents and therapeutics and thus improve delivery to cancer cells. Here
we demonstrate that nanobeads coated with “self” peptide or hCD47 injected
intravenously into NSG mice-- which express a unique SIRPα strain compatible
with human CD47—persist in circulation and exhibit enhanced perfusion,
allowing for better imaging of tumors with nanobeads.
Anti-CD47 antibodies have demonstrated preclinical activity against many
different human cancers both in vitro and in mouse xenotransplantation models
(Majeti 2009). While monotherapies targeting CD47 were efficacious in several
preclinical tumor models, combination strategies involving inhibition of the CD47–
SIRPα pathway offer even greater therapeutic potential (Chao 2012). Concurrent
administration of chemo-radiation therapy with anti-CD47 antibody is a
combination strategy that may increase efficacy. However, this approach may
also lead to increased toxicity as cell surface calreticulin is expressed on
noncancerous cells undergoing apoptosis, a principle effect of chemo-radiation
therapy (Gardai 2005, Obeid 2007). Anti-CD47 antibodies may facilitate
elimination of tumor cells through a variety of mechanisms, but the role of CD47–
SIRPα interactions in the context of antibody therapy against cancer, still need
conclusive evidence. Here we describe a therapeutic application with “self”
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peptide that it improves drug delivery when it’s combined on nanobeads with
bioactive antibody against a therapeutic target.

3.2 – Results

3.2.1 – “self”-Peptide enhances perfusion and imaging of tumors with
nanoparticles
Prolonged circulation of hCD47-beads and “self”-beads is based on a
delay of particle clearance by the spleen and liver, which rapidly accumulate
nanobeads in whole body imaging of near-infrared fluorescent beads (Fig. 3.1A).
Spleen and liver dominate biodistributions in the analysis of isolated organs in
Chapter 2 and in many studies of others (e.g. Libanov 1991, Armstrong 2000,
Photos 2003, Bartlett 2007, Rossin 2008).

Recombinant mouse-CD47 gave

results for circulation and splenic clearance similar to human-CD47 (Fig. 2.S3B),
but hCD47 seemed more important to focus on due to known differences with
mouse (Mouro-Chanteloup 2003,
experiments on human-CD47.

Subramanian 2006) and a lack of in vivo

In particular, we hypothesized that persistent

circulation of even a fraction of particles should enhance perfusion of other highly
vascularized tissues such as a subcutaneous tumor.
Human-derived A549 lung epithelial cells were xenografted in the flanks of
NSG mice, and the subsequent tumors were quantitatively imaged both in situ
and ex vivo using Near-Infrared (NIR) fluorescent nanobeads. As early as 10
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min after tail vein injection of nanoparticles, hCD47- and “self”-nanobeads gave
mean tumor intensities 2-fold above those of non-injected mice while control
beads gave background-level signal (Fig. 3.1B).

With hCD47- and “self”-

nanobeads, the fluorescence at every time point is significantly higher than
control beads (p < 0.05), and the increase fits to first order kinetics (T = 52 min),
consistent with enhanced perfusion that is limited by progressive clearance.
Notably, at 40 min, both hCD47- and “self”-nanobeads give ~10-20 fold higher
signals than controls.

A second injection of hCD47-nanobeads after 2 hrs

exhibits a similar increase in signal consistent with linearity (Fig. 3.S1A, B). An
initial doubling time for tumor accumulation of particles can be estimated as To =
12 min from the first order fit (for t << τ) and proves much shorter than control
nanobeads (T = 210 min). Both doubling times are similar to those obtained in
blood analysis for persistent circulation in chapter 2 (Fig. 2.1C), consistent with
the hypothesis that enhanced tumor signal results from persistent circulation.
Tumors and other major organs in one experiment were subsequently
excised and imaged in order to remove background from nearby tissue and
minimize any uncertainty in the region-of-interest (Fig. 3.1C). The “self”-beads
and hCD47-beads show 16- to 22-fold enhancement above the very low signals
obtained with control beads, with no statistical difference between “self”-peptide
and hCD47. The fraction of nanobeads in the blood within the tumor is small
(Fig. 3.1C, inset), and so the majority of signal derives from beads that have
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accumulated in the tumor, most likely by Enhanced Permeation and Retention
(EPR) through the leaky vasculature that is characteristic of many solid tumors
(Matsumura 1986, Cabral 2011). The NSG-mouse results are thus suggestive of
active suppression of clearance through binding of both human-CD47 and the
“self”-peptide to NSG-SIRPα on macrophages.

3.2.2 – Drug loading on the surface of nanobeads
We loaded nanobeads with Paclitaxel (Taxol), which is a common anticancer drug in wide clinical use against solid tumors as it induces cell death
through the stabilization of microtubules (Kim 2004).

The goal was to inject

various paclitaxel formulations into the tumor-bearing mouse model that was
used in the imaging studies of Fig (3.1A).
First, we tried using different concentrations of the organic solvent
Tetrahydrofuran (THF) to make the particles swell and enable drug to be loaded
into the polystyrene beads. Fig 3.2A shows the shape and size of 2.1um beads
in a water solution and Fig 3.2B shows how the particles swell when in 20%
THF. After swelling occurred, we eliminated the THF from solution and allowed
particles to return to their original size. Panel C (Fig 3.2C) provides the
polydispersions of polystyrene beads after THF treatment as measured by flow
cytometry.
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However, MTT Cell Proliferation Analysis for A549 cells after Paclitaxel
drug was loaded into the beads revealed that the particles loaded with this drug
weren’t able to release the drug to target cells and didn’t show any significance
difference with plain beads. Therefore we decided to load the particles into
polystyrene beads in water so the drug can be adsorbed into their surfaces be
later released to cancer cells to induce cell death (Fig 3.3)

3.2.3 – “self”-Peptide and anti-hCD47 on the surface of nanobeads targets
human cancer cells
Tumors were induced in mice by injection of human lung cancer derived
A549 cells, and control mice with untreated tumors received Cremophor® EL, the
castor oil-based clinical solubilizing agent that is most commonly used clinically.
This emulsifier has its own dose-limiting side effect, namely cardiotoxicity and
nephrotoxicity in vivo (Kim 2001, Gligorov 2004). We established the cytotoxic
effects of these beads in vitro (Fig 3.4A,B) and we also established the safety of
the beads along with Cremophor® EL formulations after tail vein injection (Fig
3.4E). Cremophor® EL is well known to cause allergic reactions, and the NSG
mice developed tail lesions that were severe enough to require tail amputations
in most mice, whereas the nanobeads did not exhibit such an effect (Fig 3.4F).
The nanobeads thus had a toxicity advantage. The NSG mouse results thus
reveal active suppression of clearance by both human-CD47 and ‘Self’ peptide,
thereby enhancing both tumor imaging and drug delivery.
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Efficacy was studied with two bead systems. First, we compared the nontreated mice and the Cremophor® EL-paclitaxel treated mice to the same beads
from Chapter 2, which were loaded with drug instead of dye. All of the drug
treatments suppressed tumor growth at day-4 and not earlier. However, the
CD47 beads also showed statistically significant tumor shrinkage similar to the
standard Cremophor® EL-paclitaxel (Taxol) treatments but without the noted
toxicity of Cremophor® EL (Fig. 3.4C).
Secondly, we targeted human cancer cells with antibodies against CD47.
We attached a biotinylated anti-hCD47 to the beads instead of the opsonizing
antibody (anti-Avidin), and we then showed that the anti-CD47 beads bind to
A549 cells in vitro, and any such targeting antibody still acts in vivo as an
opsonin and promotes clearance. The “self”-peptide blocks this clearance and
the anti-CD47 antibody cannot bind “self”-peptide. PEG was also attached to the
beads although it provides no advantage for antibody-targeted beads. The antiCD47 target beads with “self”-peptide suppressed tumor growth after just one
day, and were statistically better than beads without “self”-peptide (Fig 3.4D).
Tax-loaded beads that displayed either recombinant hCD47 (Fig 3.4C) or
Self-peptide plus PEG and anti-hCD47 targeting antibody (Fig 3.4D) consistently
shrunk tumors more than beads lacking ‘Self’. The ‘Self’ beads also did as well
or better than the standard paclitaxel nanocarrier Cremophor®. The NSG mouse
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results thus reveal active suppression of clearance by both human-CD47 and
‘Self’ peptide, thereby enhancing both tumor imaging and drug delivery.

3.3 – Discussion

The understanding of the CD47-SIRPα interaction is beginning to suggest
possible applications for disease, as blocking of CD47 on tumor cells allows for
tumor-associated macrophages to attack the tumor (Willingham 2012). CD47 on
nanoparticles should likewise limit uptake of nanoparticle imaging agents and
therapeutics by tumor-associated macrophages and thus improve delivery to
cancer cells. While SIRPα is abundant on macrophages and its key downstream
phosphatase SHP1 is unique to hematopoietic lineages (such as macrophages),
SIRPα is also expressed on other cell types. The A549 cancer cells used here
(Fig. 3.1) indeed express low levels of SIRPα, but we find that our nanobeads
(±hCD47) are not internalized by A549 cells in vitro compared to the THP1 cells
used in chapter 2 (Figs. 2.2E, 2.3). Enhanced imaging of tumors with hCD47
and “self”-peptide on Near-Infrared nanobeads (Fig. 3.1) is therefore likely to
result from increased tumor perfusion of the particles and the subsequent
Enhanced Permeation and Retention (EPR) effect. It should be pointed out that
a particle which stays in circulation will not guarantee delivery to a tumor site
(Hong 1999).
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We showed that “self” peptide improves delivery when combined on
nanobeads with bioactive drug against a therapeutic target, consistent with
previous results reported recently in the literature (Majeti 2009, Chao 2012, Zhao
2012, Willingham 2012). This is done in combination because chemotherapeutics
are increasingly being combined with antibodies for tumor targeting. Many
chemotherapeutics such as Taxol can kill tumor cells but will also permeate
many non-tumor tissues where cytotoxic effects limit the dose that can be
administered to patients.
Here we have shown that the drug treatments suppressed tumor growth at
day 4 (Fig. 3.4C) and not earlier. However, the CD47 beads also showed
statistically significant tumor shrinkage similar to the standard Cremophor® ELpaclitaxel (Taxol) treatments but without the noted toxicity of the Cremophor® EL
excipient.
We also reported that targeting the human cancer cells with antibody
against CD47 attached to the nanobeads coated with “self”-peptide was able to
suppress tumor growth in NSG mice after just one day of injection, which was
statistically better than beads without “self”-peptide. Even though Biotinylated
anti-hCD47 antibody acts in vivo as an opsonin and promotes clearance, the
“self”-peptide is able to block this clearance (the anti-CD47 antibody cannot bind
“self”-peptide). The upper inset in (Fig 3.4D) shows soluble hSIRPα binding to
Self-peptide on beads with anti-hCD47, which indicates that anti-hCD47 does not
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inhibit Self-peptide activity or binding. PEG was also attached to the beads as a
control, as it provides no advantage for antibody-targeted beads.
In this study, we have thus shown that nanobeads coated with “self”
peptide and anti-CD47 antibody are a promising novel therapeutic target for
cancer cells. Blocking CD47-SIRPα interaction promoted the phagocytosis of
tumor cells and inhibited their growth. In order to draw further conclusions about
the anti-cancer effects of these nanobeads, more drug doses and cytotoxic
effects need to be evaluated. Still, it is a promising idea to combine a “self”
peptide with targeting antibodies; perhaps a better delivery system such as
filomicelles or toroidal polymers rather than polystyrene beads would be
desirable as the study moves onto clinical stages.

3.4 – Materials and methods

3.4.1 – Chemicals
Dulbecco’s phosphate-buffered saline (DPBS) without Ca2+ or Mg2+
(Invitrogen) was supplemented with 1% BSA. Hoechst 33342 (Invitrogen,
Carlsbad, CA) was used for DNA stains. The near-infrared lipophilic dye, DiR,
was purchased from Invitrogen, Inc. and PKH26 Red Fluorescent Cell Linker Kit
for General Cell Membrane Labeling from Sigma Aldrich. Chloroform, methanol,
and hydrochloric acid were purchased from Fisher Scientific. N-Biotinyl-NH(PEG)4-COOH was purchased from EMD Chemicals Inc., PEG Biotin, MW 550
83

was purchased from Nanocs Inc., and mPEG-Biotin, MW 5,000 from Laysan Bio
Inc.

3.4.2 – Antibodies
The fluorescein-labeled antibody B6H12-FITC (BD Biosciences) and
mIAP301-FITC (BD Biosciences) were used against human CD47 and mouse
CD47 respectively. Opsonizing antibodies streptavidin coated polystyrene beads
(Spherotech) included rabbit anti-streptavidin (Sigma-Aldrich), rabbit antistreptavidin conjugated with FITC (Rockland Immunochemicals) and Biotin antihuman CD47 Antibody (BioLegend) were used as IgG opsonin. Secondary
antibodies used for detecting opsonin levels and uningested beads included goat
anti-rabbit FITC or goat anti-rabbit F(ab’)2 R-PE (Sigma-Aldrich). Primary
antibody used to measure the level of PEG molecules bounded to streptavidin
coated polystyrene beads was Biotin-4–fluorescein (Anaspec).

3.4.3 – Biodistribution Study with dye-labeled Beads
All mice were treated in accordance with approved IACUC protocols at the
University of Pennsylvania. Near Infrared Fluorophore (NIRF)-labeled and
unlabeled streptavidin coated polystyrene beads were injected into the tail veins
of healthy Adult Immune-deficient (NSG) Mice (4-8 weeks).

The range of

injected beads was ~107 per ml, with some variability due to accuracy of locating
the tail vein. Every 10 min, 50µl blood samples were collected by retro-orbital
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bleeding. At 35min following injection, mice were sacrificed and whole blood,
liver, spleen, lungs, kidneys, heart and brain were collected. The whole blood
was then centrifuged and plasma collected.
Organs were imaged on the LiCor Odyssey imaging system (LI-COR
Biosciences, Lincoln, NE) at 800 nm excitation. The integrated fluorescence
intensity of the organs was normalized using the organ correction factor found by
Christian et. al. (Christian 2009) and applied to all other measured intensities for
all organs. The NIR intensity of the plasma was measured on the LiCor and
calculated by fitting the slope of the linear dilution curve.
The fraction of total blood in the tumor must be estimated in order to
determine the % of injected nanobeads within the Tumor blood (Fig. 3.1C,
inset). The typical tumor weight is about 500 mg, which we approximate as 1 g,
and assume the tumor has 10% blood volume like other highly vascularized
tissues such as liver and spleen (Baxter 1994). One measurement reported
tumors are ~2% blood by volume (Jain 1988), so the assume values of 10% and
1 g provide an overestimation of the amount of NIR intensity in the tumor
provided by NIRF-labeled particles in the blood. This overestimation allows us to
safely determine that particles functionalized with “self”-peptide or hCD47 have
entered the tumor stroma.
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3.4.4 – A549 anti-CD47 binding experiments.
In a first step, A549 cells were preincubated either with 15µl of CD47B6H12-FITC at saturating levels (BD Biosciences) or with 10 µg/mL of Biotin antiCD47 antibody (Biolegend) for 30 minutes on ice. The cells were then stained
with

Cy5

conjugated

Affinity

Purified

Anti-Biotin

goat

(Rockland

Immunochemicals). After washing twice, cells were analyzed on a flow
cytometer.

3.4.5 – Biodistribution Study with Two Color-labeled Beads in Tumorbearing NSG Mice
106 human lung carcinoma A549 cells suspended in PBS with 25%
Matrigel (BD Bioscience) were injected subcutaneously into both flank sites of
each NSG mouse. After about 5 weeks, the tumor-bearing mice received tail vein
injection of the mixture of DiD and NIR dye-coated beads. Fluorescent intensity
from both dyes in tumor areas was monitored at 10min, 40min, 90min and
120min, using IVIS Spectrum Imaging System (Caliper Life Sciences, Hopkinton,
MA). After 120 min post-injection, the mice were sacrificed for harvesting tumors
as well as organs (liver, spleen, lungs, kidneys, heart, brain). Tumors and organs
were imaged on the LiCor Odyssey imaging system (LI-COR Biosciences,
Lincoln, NE) at 800 nm excitation.
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3.4.6 – Paclitaxel loading
108 polystyrene beads were suspended in 300 mL Milli-Q water. 5 mL of
4.5 mg/mL paclitaxel (LC Laboratories) in methanol was added to the beads to
achieve 75 mg/mL concentration. After overnight incubation at room temperature
and following spin-down, beads were re-suspended in PBS with 10-fold
concentration. If necessary, beads surface was modified by attaching molecules.

3.4.7 – MTT Assay
5000 A549 cells were seeded on wells of 96-well plate, 24 hours prior to
drug treatment. Cells were treated with series dilution of beads samples loaded
with paclitaxel, starting from 7.5 mg/mL. After 24 hours incubation at 37°C with
5% CO2, cells were washed once with PBS and added with 100 mL growth
medium and 20 mL of 5 mg/mL Thyazolyl Blue Tetrazolium Bromide (Sigma).
After 4 hours incubation at 37°C with 5% CO2, purple crystal in the cells were
solubilized by adding 100 mL DMSO. Absorbance was read at 560 nm.

3.4.8 – Checking body weight loss by paclitaxel-loaded beads treatment
NSG mice received intravenous (i.v.) injection of paclitaxel-loaded beads
or Cremophor® EL (Sigma) at a dose of 7.5 mg/kg. To check weight loss by
treatments, body weight of each mouse was measured right before and 24 hours
after the injection.
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3.4.9 – Tumor inhibition study
After a month of cancer cell inoculation, tumor-bearing mice were treated
with 4 daily injections (i.v.) of paclitaxel-loaded beads at a dose of 7.5 mg/kg.
Tumor size was measured on daily basis, giving an estimation of volume with
Tumor volume = ½ * (major axis) * (minor axis) 2
As a positive control for tumor shrinkage, paclitaxel solubilized with
Cremophor® EL was injected at 22 mg/kg.
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Fig.3.1.- “self”-peptide
peptide and human
human-CD47 enhance tumor imaging by NearNear
Infrared particles.
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(A) NSG mice with flank tumors of A549 lung-derived cells (black circles)
received tail vein injections of nanobead mixtures in which one bead type is
labeled with DiR fluorophore. Images of live mice and calibration standards were
taken with a Xenogen imager (IVIS Spectrum Imaging System, Caliper Life
Sciences). Tumor-bearing mice have persistence ratios of particles in blood at
35 min similar to results in Fig.2.1C, even though many particles are seen in
spleen and liver. (B) The tumor region was estimated in the brightfield image for
quantitation of total fluorescence at each time point, and all results for “self”peptide and hCD47 were combined in the fit. Results are cumulated from all
tumors from three different sets of tumor-bearing mice. N, Number of tumors. (C)
Tumors were harvested from one set of tumor-bearing mice for ex vivo
quantitation by an Odyssey imaging system (LI-COR Biosciences). For control,
N = 2; for “self”-peptide, N = 4; and for hCD47, N = 6 tumors. Inset bargraph
shows the high percentage of nanobeads in the tumor compared to an upper
bound (see Methods) for the nanobeads in the blood vessels within the tumors (n
= 2).
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Fig. 3.2.- Taxol drug loading in polystyrene beads.
(A) Optical microscope images of 2.1
2.1µm polystyrene particles in water solution.
(B) Optical microscope images of 2.1
2.1µm polystyrene particles in 80%water and
20%THF solution (C) Flow cytometry forward scatter plot for 2.1µm polystyrene
particles in water (panel left) and after adding 20%THF to the water solution
(panel right).
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Fig. 3.3.- Taxol drug loading in polystyrene beads added to A549 cells.
Bright field images at the left side and fluorescence images of Green 488
paclitaxel at the right side are shown for A549 cells after 24 hours of for A549
cells after Paclitaxel drug was added
added. The upper representative picture is
presented to illustrate the non toxicity effect of the particles in A549 cells. The
middle and bottom pictures
ctures illustrate 2 different conditions for drug loading into
A549 cells: In solution and loaded on the surface of polystyrene beads. Scale
bar, 10um.
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Fig. 3.4.- Recombinant hCD47 protein or synthetic “Self”peptide can
enhance the effect of an anti
anti-cancer drug.
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(A) In vitro viability of A549 human lung cancer derived cells in the presence of
various formulations with Paclitaxel (Tax), which is a common anti-cancer drug in
wide clinical use against solid tumors including lung tumors. Cremophore is a
standard clinical carrier of Tax. Nanobeads of the four rightmost panels are,
clockwise: IgG control with anti-Streptavidin, IgG plus biotin-hCD47 per Fig. 1C
and 2, PEG-biotin, and biotin-(anti-hCD47) (without anti-Streptavidin). Cell
viability was measured by standard MTT assay to determine the 50% inhibition
constant (IC50). (B) Targeting of A549 cells with biotin-(anti-hCD47). Upper
panel shows the cancer cells by forward/side scatter, lower left panel shows nonspecific binding of the secondary Ab Cy5-anti-Biotin, and the lower right panel
shows the specific binding between cells and biotin-(anti-hCD47). (C) Tumor
sizes 4 days after daily injections and normalized to initial A549 tumors. Control
Tax-nanobeads have anti-Streptavidin IgG (per Fig. 2.1C) and hCD47 Taxnanobeads also have this IgG; all beads were injected at the maximum drug load
of 7.5 mg/kg Tax, whereas Tax-Cremophore was injected at 22 mg/kg. None of
the drug treatments showed significant shrinkage until day-4. Tumor sizes were
measured daily. (n ≥ 3 mice; ±SEM). (D) Small molecule therapeutics are
increasingly being combined with targeting antibodies, and we hypothesized that
adding Self-peptide would provide further advantage. Tumor sizes were
measured 1 day after a single injection of targeted Control Tax-nanobeads (antihCD47 IgG + PEG) or targeted Self-peptide Tax-nanobeads (Self-pept. + antihCD47 IgG + PEG). CD47 is considered a therapeutic target on cancer cells,
and chemotherapeutics are increasingly being combined with therapeutic
antibodies as here. Note that Tax-Cremophore has no significant effect at day-1,
whereas Self-peptide effectively shrinks the tumors. (n ≥ 3 mice; ±SEM). The
upper inset shows soluble hSIRPα binding to Self-peptide on beads with antihCD47, which indicates that anti-hCD47 does not inhibit Self-peptide activity. (E)
In vivo safety of 7.5 mg/kg Tax was assessed by measuring body weight
changes 24 hr after injection (n = 3 mice each). All mice showed <10% body
weight loss, which is the conventional maximum for a tolerable dose, but TaxCremophore alone gave a statistically significant loss of body weight. (F) As part
of efficacy studies at a higher therapeutic dose of 22 mg/kg Tax-Cremophore,
visibly necrotic tails near the site of injection (images) were evident in 2 of 3 mice
injected with Tax-Cremophore, with 1 mouse requiring amputation of the tail
based on standard of care criteria. Cremophor is well known to cause allergic
reactions, but the higher dose was otherwise tolerated with weight losses <10%
body weight. The hCD47 tax-nanobeads showed no significant loss of body
weight and no tail necrosis. All data are mean ±SEM.

94

hCD47
Fig.3.S1.- Tumor imaging is enhanced after second injection of hCD47Nanobeads.
(A) Tumor imaging is enhanced after second injection of hCD47-Nanobeads
hCD47
at
120 min after first injection
injection. (B) Calibration of fluorescence emission and number
of beads using a Xenogen IVIS Spectrum Imaging System (Caliper
(
Life
Sciences, Hopkinton, MA).
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CHAPTER 4 – Modeling the implications of SIRPα binding to
CD47 in cis (on the same cell surface) on SIRPα's ability to bind
to CD47 in trans (on target cells)

Pia L. Rodriguez, Richard K. Tsai, Diego Pantano and Dennis E. Discher

Dr. Tsai provided the generation of the lentivirus knockdown on CD47, the
expression studies in CHO cells and helped with sheep phagocytosis. Also he

provided general discussion of the subject. Dr. Pantano provided the Normal mode
analysis of SIRPα.
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Abstract

A large number of membrane proteins possess extracellular domains that
interact with extracellular domains of other membrane proteins, transducing
important signals to cells. Such interactions can occur either in cis (both proteins
on the same cell’s surface) or in trans (proteins embedded in membranes of
different cells.) These two possibilities raise important questions about the
differences between signaling that occurs in cis vs. in trans. Many cells express
not only the ubiquitous 'Marker of Self' protein CD47 but also some level of its
counter-receptor SIRPα (CD172). Here we show that CD47-SIRPα interactions
occur not only in trans in cell-cell adhesion, but also in cis, modulating
downstream

signals.

Activation

is

clearly

increased

with

CD47-SIRPα

interactions in trans, resulting in the inhibition of phagocytosis of any CD47displaying target. Knocking down CD47 on macrophages decreases the level of
basal signaling, increases binding of soluble CD47, and enhances phagocytosis
of opsonized targets above wild-type cells. When multiple knockdowns are
performed, the effective Kd for binding in trans is shown to depend linearly on cis
CD47 on the macrophage, consistent with the simplest mathematical modeling
for cis vs. trans competition. Cis interactions might be unavoidable with this
system and others studied, but it is also possible that by lowering the threshold at
which activation exceeds inhibition, cis interactions may optimize discrimination
in trans.
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4.1 – Introduction

Macrophages like other innate immune cells have the ability to clear
foreign and apoptotic cells. The recognition of these foreign or host cells is
induced through direct recognition by conserved receptors such as complement
and Fc receptors that lead to clearance by phagocytosis (Tenner, Robinson et al.
1995; Ravetch 1997). Recognition of foreign cells may occur through antigen
recognition, resulting in IgG opsonization (Ravetch and Clynes 1998) that is not
limited to foreign cells, but autologous cells as well (Turrini, Mannu et al. 1993).
Binding of macrophage Fcγ-R to IgG opsonin on a target cell leads to extension
of pseudopodia, creating a phagocytic synapse that “zipper” around the target
with increasing activation signal (Swanson and Baer 1995). However when host
cells express CD47 and IgG-opsonized they are recognized by receptors
transmitting both activating and inhibitory signals to the macrophage. The
inhibitory signal is occurs when self cells express CD47 that bind to the immune
inhibitory receptor, SIRPα (Seiffert, Cant et al. 1999). The integration of these
signal inputs determines whether the target cells will undergo clearance.
This ubiquitously expressed protein CD47 protein is an Ig
superfamily member that interacts specifically with SIRPα found on macrophages
(Jiang, Lagenaur et al. 1999; Seiffert, Cant et al. 1999; Vernon-Wilson, Kee et al.
2000). This receptor-ligand interaction signals self in macrophages, enabling
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selective phagocytosis of foreign cells or particles. Phosphorylation of the
immune-receptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic domain
of SIRPα upon ligation with CD47 leads to the recruitment of SHP-1 and
deactivation of phagocytosis (Vernon-Wilson, Kee et al. 2000; Seiffert, Brossart
et al. 2001). The loss of CD47 protein in red blood cells (RBCs) and apoptotic
cells results in the susceptibility of these self cells to clearance by macrophages
(Oldenborg, Zheleznyak et al. 2000; Anniss and Sparrow 2002; Krieser and
White 2002; Gardai, McPhillips et al. 2005).
The receptor SIRPα is composed of three IgSF domains while
CD47 contains only a single IgSF domain with a disulfide link between one of the
loops between the transmembrane regions (Tsai, 2008), which may be required
for optimal binding of SIRPα (Rebres, Vaz et al. 2001). The crystal structure of
SIRPα-CD47 complex indicates that the loops of SIRPα are highly flexible, and
that CD47 binds at the N-terminal ligand-binding domain of SIRPα (Hatherley,
Graham et al. 2008). CD47 has a high specificity to SIRPα. The regions of the
mammalian brain in which CD47 is particularly abundant overlap substantially
with those enriched in SIRPα (Mi, Z.P. et al. 2000, Ohnishi, H. et al. 2005). The
similar expression patterns of SIRPα and CD47 in the brain indicate that the
transinteraction of the two proteins mediates intercellular signaling in a
bidirectional manner. By contrast, SIRPα is barely detectable in red blood cells
(RBCs) or in T or B lymphocytes, whereas CD47 is expressed in a variety of
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hematopoietic cells (Adams, S. et al. 1998, Veillette, A. et al. 1998, Seiffert, M. et
al. 1999, Seiffert, M. et al. 2001, Brown, E.J. and Frazier, W.A. 2001). CD47 or
SIRPα might thus mediate unidirectional signalling in the hematopoietic or
immune systems. For instance, the binding of CD47 on RBCs (in which minimal
expression of SIRPα exists) to SIRPα of macrophages regulates phagocytosis by
macrophages in a unidirectional manner (Matozaki, Murata et al. 2009). CD47
binding to SIRPα is relatively low affinity, and is less important for cell-cell
adhesion (Hatherley, Harlos et al. 2007; Subramanian, Boder et al. 2007). The
lower affinity interaction of CD47-SIRPα allows for rapid interaction on the
macrophage surface from intracellular (cis) to intercellular (trans) binding to
target cells.
Expression of both SIRPα and CD47 on the surface of macrophages
raises the possibility that these proteins interact on the same macrophage
surface (in cis). If so, this would have implications for SIRPα’s ability to bind to
CD47 on target cells (in trans) (Doucey, Scarpellino et al. 2004). To explore the
possibility that SIRPα and CD47 can interact in cis, we used a CHO cell display
system. CHO cells expressing human SIRPα were co-expressed with or without
human CD47. We demonstrated that the binding excluded simultaneous cis and
trans interaction due to a specific binding site in the SIRPα receptor (Hatherley,
Harlos et al. 2007). The functional implication of cis interaction was demonstrated
with CD47 knockdown macrophages that indicated higher level of phagocytosis
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of IgG-opsonized sheep RBCs. This was a consequent of the loss of the
inhibitory signal associated with CD47-SIRPα interaction via cis. However this
had no effect on the phagocytosis of IgG-opsonized human RBCs. From our
earlier studies with human macrophages, the phagocytic synapse extended but
eventually retracted. This delayed retraction occurs due to the competitive
binding of SIRPα with CD47 from cis on macrophage surface to trans on target
cells.

4.2 – Results

4.2.1– Expression profiles of CD47 and SIRPα in human cells
CD47 expressed on the surface of self cells prevents elimination of these
cells by binding to the inhibitory receptor SIRPα on the surface of phagocytes.
Once it is activated, SIRPα inhibits pro-phagocytic signals from Fc and
complement receptors, resulting in inhibition of phagocytosis (de Almeida 2009).
In agreement with previous reports (Brown and Frazier 2001), flow cytometry
analysis revealed that all cells (both professional and non-professional
phagocytes) express CD47 (Fig. 4.S1 and 4.S2). The level of CD47 expression
was high in red blood cells compared to other eukaryotic cells explored based on
total CD47 expression. Mature RBCs express high copies of CD47 protein on the
surface because they are unable to further express CD47 after erythropoiesis
(Furusawa, Yanai et al. 1998) unlike other eukaryotic cells. As RBCs age the
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level of CD47 proteins are reduced that eventually lead to clearance (Anniss and
Sparrow 2002). However we have previously reported that only 10-20% CD47
density of normal human RBC (hRBC) is necessary to inhibit uptake by human
macrophages (Tsai and Discher 2008). In each of the cell types explored, the
number of CD47 molecules was above the necessary minimum of ~20 CD47
molecules/µm2. In contrast to CD47, we found that SIRPα expression was
restricted to phagocytes, including human THP-1 macrophages, peripheral blood
monocytes (PBMC) and, in lower levels, human mesenchymal stem cells (MSC).
One interesting observation was that human hematopoietic stem cells displayed
SIRPα expression that was very similar to the one found in THP-1 macrophages,
but only after being cultured and induced with granulocyte colony-stimulating
factor (G-CSF) for 7 days (Fig. 4.1A). The expression of SIRPα on MSC is in
agreement with other studies (Vogel, Grunebach et al. 2003) suggesting that
these cells express Fcγ-R and exhibit low phagocytic capabilities (Charriere,
Cousin et al. 2006). THP-1 macrophages and MSC had a ratio of 3.2 and 10.9
CD47 to SIRPα molecules respectively (Fig. 4.1). This was calculated based on
flow cytometry analysis using antibodies against CD47 and SIRPα to obtain the
ratio in unpermeabilized live cells. In both cell types the total level of CD47 was
observed to be higher than total level of SIRPα suggesting that macrophages can
signal self when in contact with other macrophages.
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To address the molecular basis of the reduced inhibition through SIRPα in
the presence of CD47, we sought to explore the phosphorylation signal that
associates with CD47-SIRPα ligation. SIRPα interaction by trans with targets
presenting CD47 (Fig. 4.2A) triggers SIRPα’s immunorecptor tyrosine-based
inhibiting motif (ITIM) activation (Kharitonenkov, Chen et al. 1997) and
subsequent SHP-1 phosphatase induction (Brown and Frazier 2001; Latour,
Tanaka et al. 2001), ultimately leading to the inhibition of phagocytosis. Previous
studies showed an inherent endogenous SIRPα phosphorylation in macrophages
alone without the presence of IgG-opsonized targets (Oldenborg, Zheleznyak et
al. 2000; Ide, Wang et al. 2007; Tsai and Discher 2008) which may be attributed
to the cis interaction on macrophages that we observed in our studies above.

4.2.2 – Reduced SIRPα function and foreign cell phagocytosis
In order to directly assess the function of the cis interaction on
macrophages, CD47 expression was suppressed using RNA interference. The
expression of CD47 was reduced to levels ranging from 13% to 50% wild-type
levels (Fig. 4.S3A) while the levels of SIRPα on these macrophages remained
unchanged.
As observed in the CHO cell system, the level of soluble hSIRPα trans
interaction was reduced (Fig. 4.6C) we sought to explore the difference in
binding affinity in THP-1 macrophages at physiological levels of CD47 and SIRPα
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as opposed to the extreme overexpressions of CD47 co-expression with SIRPα
on CHO cells. The macrophages tested demonstrated a moderate affinity and
saturable interaction of hSIRPα for CD47 in wild-type and the two CD47 blocking
antibody (Fig. 4.3A). The binding affinity in wild-type (WT) THP-1 macrophages
was 1.6 µM with increasing binding affinity to 0.26 µM in cells with blocking antihCD47 antibody B6H12 (clone with high specificity to hCD47 protein) and the
binding affinity remain the same in the case of blocking anti-hCD47 antibody 2D3
used as a negative control due to its low specificity to hCD47. The binding affinity
increased to 0.26 µM in cells with ~13% wild-type CD47 levels (CD47′ THP-1
cells) and to 0.87 µM in cells with ~48% wild-type CD47 levels (Fig. 4.3B). A
linear relationship was observed in relation to CD47 expression level and the
measured dissociation constant, Kd where the reduction or elimination of the cis
interaction between CD47 and SIRPα led to a higher binding affinity with soluble
hCD47 (Fig. 4.3C). The reduction of CD47-SIRPα cis interaction led to a linear
decrease in tyrosine phosphorylation (Fig. 4.4B). These results suggest that
CD47-SIRPα may affect the efficiency of macrophages to differentiate non-self
and self because of the inherent phosphorylation signal associated with cis
interaction.
In order to understand the role of CD47-SIRPα cis interaction in
phagocytosis, IgG-opsonized sheep and human red blood cells (RBCs) were
used as targets for THP-1 macrophage WT and CD47′ THP-1 cells.
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Phagocytosis by THP-1 macrophages was studied by imaging in differential
interference contrast (DIC) microscopy and quantified by the number of ingested
RBCs per macrophage. The internalization of sheep RBC was seen to increase
by 20% with CD47′ THP-1 cells compared to wild-type macrophages, but human
RBC targets showed no statistical difference (p = 0.12) (Fig. 4.5A). We used two
CD47 suppression vectors that showed no difference in phagocytosis of human
RBCs compared to WT THP-1 macrophages. In order to assess that lentiviral KD
did not impact THP-1 macrophages phagocytic capabilities, a mock knockdown
was performed that showed IgG-opsonized ShRBC had comparable level of
phagocytosis to THP-1 WT and knockdown (KD) controls (Fig. 4.S5).
RBCs are common targets used in phagocytosis studies, but RBC
membranes are complex. We therefore tested whether particles with or without
CD47 had similar trends as observed with the RBC targets. The extracellular
immunoglobulin-like domains of human CD47 (hCD47) was recombinantly
expressed and attached to streptavidin-coated particles (2.1 µm). To study
phagocytosis, beads were IgG-opsonized by pre-treatment with anti-streptavidin
to induce FcγR-mediated phagocytosis (Tsai and Discher 2008). As with our
RBC studies (Fig. 4.5A), a ~50% higher level of phagocytosis of uncoated beads
was observed in 13% WT CD47 compared to WT THP-1 (Fig. 5B). Particles
coated with hCD47 at the lower limit necessary for inhibition (~24 CD47
molecules/µm2) showed no difference in phagocytosis. The results from both the
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RBC and particle targets showed an increase in phagocytosis of non-self targets
due to lower cis interaction.
In order to determine if CD47 and SIRPα indeed interact in cis, we sought
to explore the extreme case by overexpressing both proteins in a model CHO
display system where expression levels can be controlled (Subramanian, Boder
et al. 2007). We first compared the effect of CD47 on protein localization on the
surface. CHO cells co-expressed with human SIRPα showed a reduced level of
antibody binding compared to hCD47-GFP expression alone (Fig. 4.6A). The
level of anti-hCD47 antibody bound was drastically reduced in cells coexpressing hCD47-GFP and hSIRPα across the different levels of hCD47-GFP
expression suggesting a competitive interaction (Fig. 4.6B). Similar to the
observations with anti-hCD47 antibody hSIRPα bound signal was reduced to
near background levels in CHO cells co-expressing hCD47 and hSIRPα (Fig.
4.6C).

4.2.3 – SIRPα and CD47 physically associated in cis
In order to determine if CD47 and SIRPα indeed interact in cis, we sought
to explore the extreme case by overexpressing both proteins in a model CHO
display system where expression levels can be controlled (Subramanian, Boder
et al. 2007). We first compared the effect of CD47 on protein localization on the
surface. Fluorescent microscopy images of unpermeabilized CHO cells
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expressing hCD47-GFP showed localization of anti-hCD47 antibody labeling and
soluble human SIRPα (hSIRPα) confirmed pool of hCD47-GFP was properly
displayed on the surface and functional (Fig. 4.6). In order to rule out the
possibility that the co-expression of hSIRPα was masking the epitope for the
CD47 antibody (clone 2D3), a number of additional antibodies were used each
recognizing different epitopes of human CD47 confirmed the above results of
reduced binding (Fig. 4.S6B). Poor multimeric binding to SIRPα in the presence
of CD47 may be the due to steric hindrance as a result of direct or indirect
association within the plane of the same membrane (in cis).

4.3– Describing a model for the competitive binding between CD47-SIRPα
in cis and in trans interactions

In order to understand the competitive binding occurring during the
interaction of SIRPα and CD47 in cis or in trans, we developed an equilibrium
model (Fig. 4.3). We assumed that the two CD47 ligands—denoted as trans (Ct)
or cis (Cc)-- could only occupy a single site on the macrophages SIRPα (Sv)
(Rebres, Kajihara et al. 2005; Takenaka, Prasolava et al. 2007). Binding constant
for cis and trans interactions was defined as Kc and Kt respectively. We began
calculating the fractional occupation of the site, θ by trans-CD47 (Eq. 1.1).
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θ=

K t Ct
1 + K c Cc + K t Ct

(Eq. 4.1)

The free receptor SIRPα and ligand concentration CD47 was related to
the chemical equilibrium through the dissociation constant, Kd (koff/kon) while the
chemical potential was simultaneously related with the fraction occupation site
(Eq. 1.2) (Hill 1985).

Kd =

1 + K cCc
Kt

(Eq. 4.2)

This model validates the experimental results that the affinity binding
constant had a linear behavior (Fig. 4.3C) and confirms that the effective affinity
of trans-CD47 (Ct) for free SIRPα (Sv) is a function of cis-CD47 (Cc)
concentration. The accessibility of SIRPα to soluble CD47 in trans was shown to
have a slower binding with an association constant kon of 0.65min-1 in WT
compared to 0.36 min-1 in CD47′ THP-1 cells (Fig. 4.S4).

4.4 – Discussion

In this study we have shown that the signal regulatory protein (SIRPα)
found on macrophages binds to CD47 ligand expressed on target self cells but is
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also constitutively associated with CD47 in the plane of the macrophages
membrane (cis interaction). It has been well characterized that the self signal of
SIRPα and CD47 inhibits macrophages in mouse (Oldenborg, Zheleznyak et al.
2000; Gardai, McPhillips et al. 2005) and humans (Tsai and Discher 2008)
through a trans interaction. We proposed that the cis interaction exists and
restricts the extent to which SIRPα inhibits macrophage phagocytosis of non-self
cells lacking CD47.
We addressed the importance of CD47 in cis on macrophages due
to the necessity of the protein to function as a marker of self on all cells. Two
types of THP-1 macrophages, wild-type and 13% WT CD47 showed equal
phagocytic activity against self targets human RBCs and hCD47 coated particles.
In contrast, phagocytosis was increased by 25-50% for foreign or uncoated
“CD47-null” particles in THP-1 cells with reduced cis interaction (Fig. 4.3). In
order to rule out the possibility of knockdown effect on THP-1 phagocytosis
capabilities, SIRPα expression was confirmed for all knockdowns by flow
cytometry and a mock lentiviral KD was shown to have comparable phagocytosis
capabilities to WT THP-1 Cells (Fig. 4.S5). This suggests that the cis interaction
of CD47-SIRPα may negatively inhibit macrophages regardless of targets due to
the inherent signal.
Phagocytosis initiated by the activation of Fcγ-R on macrophages
through binding to IgG-opsonized targets leads to the phosphorylation of the
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immune-tyrosine activation motif (ITAM) (Cambier 1995; Lowry, Duchemin et al.
1998). Alternatively an inhibition signal exists with self cells expressing CD47 that
interaction with the receptor SIRPα that results in the inhibition of phagocytosis.
The

CD47-SIRPα

interaction

has

been

shown

to

be

species-specific

(Subramanian, Parthasarathy et al. 2006) and normal macrophages have been
shown to engulf “self” cells at lower frequency than typical targets – foreign and
apoptotic cells or particles. Self cells signal inhibition through CD47-SIRPα
interaction in trans results in the recruitment of the SHP-1 phosphatase, but
inherent phosphorylation has been shown to exist in macrophages that may
suggest the inefficiency of recognizing non-self and self cells as demonstrated by
with Sheep RBCs with human THP-1 macrophages (Fig. 4.5A). However when
CD47 coated particles or RBCs interact with SIRPα of the same species, this
results in increased phosphorylation that reaches a saturating level dependent on
CD47 density (Vernon-Wilson, Kee et al. 2000; Liu, Soto et al. 2005).
SIRPα affinity to CD47 is relatively low affinity interaction with a Kd
of 1.6 µM that allows for rapid exchange of CD47-SIRPα binding from an
intracellular cis to a intercellular trans interaction (Fig. 4.3). Further confirmation
of the competitive binding was demonstrated through measurement of the
association constant, kon showing a slower rate for wild-type macrophages
suggesting the availability of the CD47 to interact by trans was occupied by
CD47 in cis (Fig. 4.S4). The basal level of SIRPα activation suggests the
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threshold difference needed for inhibition may be local. Soluble CD47 in solution
with foreign sheep RBC did not have a significant effect in inhibiting phagocytosis
(data not shown), but a local concentration of SIRPα and CD47 clustering at the
phagocytic synapse may be necessary to signal self. When human macrophage
attempts to engulf its targets through pseudopod extension it verifies the
presence of CD47 as in normal human RBCs. This spurs the macrophage to stop
mid-swallow, shifting from an intracellular cis to an accumulated intercellular
trans signal (Tsai and Discher 2008). The observed delayed retraction of human
RBCs may serve as a function for microbe clearance through CR1 receptor
found on RBCs where microbe would be removed during macrophage contact
(Ghiran, Glodek et al. 2008).
Normal THP-1 macrophages have a higher ratio of CD47 to SIRPα by a 3to-1 ratio but in our highest CD47 knockdown the ratio dropped to 0.5-to-1
resulting in more SIRPα than CD47. That led to a decrease in SIRPα
phosphorylation levels that fit linear to the extent of CD47 expression (Fig. 4.4B).
This elimination of phosphorylation by cis interaction led to a better discrimination
of foreign and self cells with a 25-50% increase in phagocytosis of IgG-opsonized
ShRBC and uncoated particles. It is interesting to note that the reduction of cis
interaction in THP-1 macrophages did not significantly affect HuRBC and hCD47
coated particles.
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Our finding raises the question of how SIRPα is able to bind with
CD47 both in cis and trans interaction at the binding site. A past crystallographic
study showed that the CD47/SIRPα complex binds near the N-terminal ligand
binding domain of SIRPα (Hatherley, Graham et al. 2008). SIRPα and other
members of the SIRP family have three IgSF domains while CD47 contains only
a single IgSF domain; this suggest that SIRPα may have some flexibility in the
structure as the binding site is near the N-terminus as it was shown with the
computed flexibility model (Fig. 4.2). However the structure of CD47 is unique
because of the disulfide link between the IgSF domain and one of the loops
between the transmembrane regions was shown to be required for optimal
binding of SIRPα (Rebres, Vaz et al. 2001).
In order to account for our findings, our model suggests that SIRPα
inhibits phagocytosis through CD47 and SIRPα by trans while foreign target cells
are not able to signal self leading to activation Fcγ-R by IgG-opsonization. In
wild-type macrophages both cis and trans CD47-SIRPα interaction co-exists with
the presences of a basal level of inhibitory signal regardless of self or foreign
cells. The importance of CD47 and SIRPα by cis appears to partially affect
phagocytosis of foreign particles, but it is important for macrophages to maintain
their own display of the “marker of self” signal, CD47 to prevent phagocytic
clearance by other macrophages.
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4.5– Materials and Methods

4.5.1 – Chemicals
Dulbecco’s phosphate-buffered saline (DPBS) without Ca2+ or Mg2+
(Invitrogen) was supplemented with either 1% BSA or 1% BSA and 0.05%
Tween 20 (Sigma-Aldrich).

4.5.2 – Antibodies
The anti-human CD47 antibody B6H12 (BD Biosciences), clone 2D3
(EMD Biosciences), clone 6H9 a gift from Dr. M. Telen (Duke University) was
used for detection of human CD47 on macrophages or CHO cells expressing full
length human CD47. Quantification of CD47 and SIRPα was performed using
B6H12-FITC and anti-SIRPα (SE7C2) (Santa Cruz Biotech) respectively. Human
SIRPαex (this laboratory) used for experiments comparing binding affinities
between species. Opsonizing antibodies against sheep RBCs included rabbit
anti-sheep RBCs (Sigma-Aldrich) and antibodies against streptavidin coated
polystyrene beads (Spherotech) included rabbit anti-streptavidin (Sigma-Aldrich)
and rabbit anti-streptavidin conjugated with FITC (Rockland Immunochemicals)
was used as IgG opsonin in phagocytosis assays. Secondary antibodies used for
detecting opsonin levels and uningested beads included goat anti-rabbit FITC or
goat anti-rabbit F(ab’)2 R-PE (Sigma-Aldrich). Secondary antibodies used for
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detecting SIRPαex binding included anti-GST Alexa 488 (Invitrogen). Cytokine GCSF was purchased from R&D Systems.

4.5.3 – Cells culture and transfection
COS-1, CHO-K1, A549, THP-1 cells (American Type Culture Collection)
and Human mesenchymal stem cells (MSCs; Osiris Therapeutics) were
respectively maintained in DMEM, MEMα, F-12, RPMI 1640, and DMEM low
glucose media (Invitrogen) supplemented with 10% heat inactivated FBS (SigmaAldrich). Cells were detached using 0.25% Trypsin/0.5mM EDTA (Invitrogen) for
passaging. Differentiation of THP-1 cells was achieved in 100 ng/mL phorbol
myristate acetate (PMA) (Sigma-Aldrich) for 2 days and confirmed by attachment
of these cells to tissue-culture plastic. Peripheral blood monocytes from human
donors were obtained through the Human Immunology Core (University of
Pennsylvania). Human blood was obtained from finger pricks of healthy donors.
Blood from other species was obtained from Covance and washed 3x in PBS
plus 0.4% BSA. Human Hematopoietic Stem Cells were obtained from Fresh
purified bone marrow (BM)-derived humanCD34+ cells from Lonza. All
experiments were performed in hematopoietic stem cell (HSC) expansion media
(StemLine-II; Sigma) and supplemented with 1× antibiotics and G-CSF (100
ng/mL) for 7 day for cultured cells.
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4.5.4 – Expression of human CD47-GFP and SIRPα
Human CD47 (hCD47; isoform 2 (Reinhold, Lindberg et al. 1995)) were
PCR amplified, digested with XhoI & BamHI (New England Biolabs) and ligated
to similarly digested vector, pEGFP-N3 (Clontech laboratories). CHO cells were
plated at 1 x 105 cells/cm2 a day prior to transfection. On the day of transfection,
medium was replaced with 2 mL Opti-MEM I (Invitrogen) per 25 cm2 surface
area and 10-15 µL Lipofectamine 2000 and 5 µg plasmid DNA were diluted in
0.25 mL Opti-MEM I separately and 5 min later mixed and incubated for a
minimum of 20 min at 25°C. Lipid-DNA complexes in a total volume of 0.5 mL
Opti-MEM I was added to the flasks and incubated for 4-6 hrs and then replaced
with fresh growth medium. Transfected cells were harvested using DPBS
supplemented with 2 mM EDTA (Invitrogen) 1-2 days post-transfection for
analysis.

Full-length human SIRPα was expressed in CHO cells similar to

human CD47-GFP above.

4.5.5 – Soluble human SIRPα production
COS-1 cells were transfected with pcDNA3-based vector (Seiffert, Cant et
al. 1999) encoding a human SIRPα extracellular domain fused to GST using
Lipofectamine 2000 (Invitrogen). Secreted SIRPα1-GST (referred as hSIRPαex)
was affinity-purified using Glutathione Sepharose 4B (Amersham Biosciences)
and dialyzed against PBS (Invitrogen). The protein was stored at -20°C with or
without addition of 10% v/v glycerol (Fisher Scientific).
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4.5.6 – Production of recombinant human CD47
Plasmid encoding the extracellular domain of human CD47, mouse CD47
were PCR amplified, digested with XbaI & SalI (New England Biolabs) and
ligated to similarly digested vector, pEF-BOS-XB (Vernon-Wilson 2000), which
results in an in-frame fusion of CD4d3+4-biotin at the c-terminus of the
extracellular domain of CD47. The above vector containing the extracellular
domain of CD47 was transfected into CHO(-K1) cells using Lipofectamine 2000
(Invitrogen). Secreted CD47-CD4d3+4 was concentrated using a 10K MWCO
Amicon (Millipore) and biotinylated at the c-terminus using a biotin-protein ligase
(Avidity, LLC) and dialyzed against PBS (Invitrogen). The protein was affinitypurified using a monomeric avidin (Promega) and dialyzed against PBS.

4.5.7– Measurement of human SIRPα and CD47 on cells
Human RBCs, THP-1 cells, A549, peripheral blood monocytes, human
mesenchymal stem cells were labeled with 15µl of B6H12-FITC at saturating
levels (BD Biosciences) against human CD47 for 30 min at room temperature.
Cells were washed and resuspended in PBS for flow cytometry analysis. Antihuman CD47 measurements and detections were performed using B6H12
antibody. Saturating concentration of anti-SIRPα or anti-human CD47 antibodies
were used as similarly described for the above cells.
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4.5.8 – Lentiviral knockdown of CD47 in THP-1 cells
ShRNA lentiviral supernatants to CD47 purchased from Sigma-Aldrich
were targeting CD47 (TRC#: TRCN0000007836, TRCN0000007837) resulted in
50-87% knockdown, respectively. Further details of these clones are available
from Sigma-Aldrich website. Target THP-1 cells were infected with lentiviral
supernatants at a multiplicity of infection (MOI) of 10 in the presence of 80 µg/mL
Polybrene (hexadimethrine bromide) (Sigma-Aldrich) and remained in culture for
24 hours at 37°C and replaced with fresh RPMI 1640 + 10% FBS. Cells with
integrated viral sequence were selected using puromycin (Sigma-Aldrich) at 2
µg/ml and then passaged with continuous puromycin selection. The degree of
CD47 silencing was regularly monitored by flow cytometry and Western blotting
with 1:200 anti-SIRP (SE7C2) (Santa Cruz Biotech). Control cell cultures were
generated with control lentiviruses in parallel.

4.5.9 – Binding isotherm for soluble hSIRPα for THP-1 and knockdowns
The binding isotherm of soluble hSIRPα was performed for THP-1 wildtype and CD47 knockdowns as noted over a range of concentration using flow
cytometry. Forward scatter, side scatter and fluorescence (FL1, FL2, FL3, FL4
channels in logarithmic mode) were acquired using a FACScan or FACSCalibur
(BD Immunocytometry Systems). Data points from flow cytometry were plotted
and fitted to obtain the Kd values as shown.
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4.5.10 – Kinetics Measurements
Rates of association (kon) of SIRPα with soluble hCD47 were measured
at room temperature. Mixtures of 8uM,4uM and 2uM soluble hCD47 with 15l of
B6H12-FITC against human CD47 at saturating levels (BD Biosciences) were
preequilibrated for 3 hours to produce the primary complex. After mixing, aliquots
were periodically withdrawn and added to the human THP-1 cells, then washed
and diluted in PBS (1:30) to measure the hCD47 and SIRPα binding using flow
cytometry. Forward scatter, side scatter and fluorescence (FL1, FL2, FL3, FL4
channels in logarithmic mode) were acquired for at least 104 events using a
FACScan or FACSCalibur (BD Immunocytometry Systems). Data points from
flow cytometry were plotted and fitted to obtain the Kon values as shown.

4.5.11 – Phagocytosis Assay
For phagocytosis assays, macrophages were plated in 4cm2 Lab-Tek II
Chambered Coverglass (Nalge Nunc International) at 1 x 105/4cm2. Streptavidin
polystyrene beads or RBC were added to macrophages at a ratio of 20:1 and
allowed to incubate at 37˚C for 45 min. Non-phagocytosed beads or RBCs were
washed with PBS. Cells were fixed with 5% formaldehyde (Fischer Scientific) for
5 min, followed by immediate replacement with PBS. For differentiation of noninternalized beads, beads were labeled with a primary antibody, rabbit antistreptavidin (Sigma) at 1:1,000 in PBS for 20 min at 25°C. A second antibody,
anti-rabbit R-PE (Sigma) was added at 1:1,000 in PBS to the cells and incubated
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for an additional 20 min at 25°C. Cells were then w ashed with PBS/ 0.4% BSA
and then quantified by light and fluorescent microscopy. At least 200 cells were
scored per well and experiments were repeated at least three times. Assays
using RBCs as targets, lysis of uningested RBC was performed by adding
deionized H2O for 60s, followed by immediate replacement with PBS/0.4% BSA
and fixing with 5% formaldehyde for 5 min.
For stimulated phagocytosis assays, beads with or without CD47
were incubated with rabbit anti-streptavidin serum and for sheep and human
RBCs with rabbit anti-sheep RBC, and rabbit anti-human RBC respectively as
the opsonin. Beads or RBCs were opsonized at the respective concentration for
30 min at RT. Opsonized beads and RBCs were washed 2x and resuspended in
50 µl of PBS/0.4% BSA. Phagocytes were washed with PBS and uningested
RBCs were lysed and uningested beads were labeled as described above.

4.5.12 – Immunoprecipitation and Western blotting
Human Phagocytes, THP-1 wild-type and CD47 knockdowns (2x106) were
cultured and differentiated in 6-well plates for 48 hours after PMA differentiation.
Human CD47 was attached to 2.1µm diameter beads at specific densities as
described above and added at a bead to cell ratio of 20:1 for 10 minutes.
Following the incubation time, the cells were washed with ice-cold PBS and then
lysed on ice in 300 µl of lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
121

1mM EDTA, 1% NP-40, 1% protease inhibitor cocktail [Sigma-Aldrich] and 2mM
activated sodium orthovanadate). For immunoprecipitation, whole lysate was
mixed with 1:200 anti-SIRPα (SE7C2) antibody (Santa Cruz Biotechnology, Inc.)
with Protein G agarose (Pierce) at 4˚C overnight. Precipitated proteins was
placed in 4-12% SDS-PAGE in MOPS buffer (Invitrogen), transferred to PVDF
membrane, blocked and labeled via phosphotryosine IgG HRP-conjugated (Cell
Signaling) and anti-SIRPα (C-20) (Santa Cruz Biotechnology, Inc.) as primary
antibodies and anti-goat-HRP (Amersham). All Westerns were run in duplicate,
along with an additional blot for actin to ensure constant protein load among
samples.

4.5.13 – Fluorescent labeling of transfected CHO with soluble SIRPα and
CD47 antibodies
Five microliters of soluble SIRPµ (final concentration ~1 µM); 5 µl of 2
mg/ml AlexaFlour 647 rabbit anti-GST; 40 µl DPBS, 1% BSA; and 2.5 x 106 CHO
cells were mixed and incubated at room temperature for at least 30 min. Cells
were pelleted and resuspended in 1 ml cold DPBS and analyzed immediately.
For antibody labeling, saturating levels of anti-CD47 antibody in 50 µl of DPBS,
1% BSA and 2.5 x 106 CHO cells were mixed together and incubated as above.
Cells were washed in 0.5 ml of DPBS, 1% BSA and then resuspended in 50 µl of
DPBS, 1% BSA containing 5 µl of secondary antibody (2 mg/ml). After incubate
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for 30 min at room temperature, cells were washed once in 0.5 ml of DPBS and
resuspended in 1 ml of DPBS, 1% BSA and used immediately for imaging.

4.5.14 – Quantification of fluorescent intensity
Images were acquired with an inverted microscope (Olympus; IX71) with a
60x (oil, 1.4 NA) objective using a Cascade CCD camera (Photometrics, Tuscon,
AZ). Image acquisition was performed with Image Pro software (Media
Cybernetics, Silver Spring, MD). All subsequent image analysis was done using
ImageJ.

4.5.15 – Normal Mode Analysis of SIRPα structure
To gain insight about the degree of flexibility and mobility of the Signalregulatory protein α (SIRPα) we employed Normal Mode Analysis technique. For
this purpose we used the α-carbon backbone of the recently published crystal
structure for SIRP-α1 as model (PDB: 2WNG). Our first goal was to detect the
presence of hinges. This is a challenging problem when only one structure is
known and several algorithms and techniques have been developed to tackle it.
(Thorpe et al. 2001; Wells et al. 2005; Flores et al. 2006; Flores et al. 2008). Our
approximation will use the Gaussian Network Model which assumes that all the
residue fluctuation around their equilibrium coordinates are gaussian. (Bahar et
al. 1997; Haliloglu et al. 1997). This method has been tested to be suitable to
determine structural displacements and consequently backbone motional
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correlations. By virtue of these correlations, the different domains in the protein
are determined as well as the location of the hinges. (Kundu et al. 2004; Haibo et
al. 2007)The normal modes have been obtained using a rcutof f = 15Å and the
correlations between them were computed using the following expression:

Cij =

∆ri ⋅ ∆rj
∆ri

2

∆r j

2

,

(Eq. 4.3)

where ∆ri is the total displacement of the α-carbon of the i-th residue from its
equilibrium position due to the first n normal modes, and

κ BT Lik L jk
,
2
mi m j
k =1 ωκ
n

∆ri ⋅ ∆rj = ∑

(Eq. 4.4)

where ωκ2 is the frequency of the k-th normal mode and Lik is the displacement of
the α-carbon of residue i due to normal mode k.
The result of this correlation for the first two lowest frequency modes is
shown in (Fig. 4.2). It is possible to distinguish three different regions that
correspond very accurately with the three domains present in the crystal
structure. The regions along the diagonal which values close to zero, i.e. regions
with reduced mobilities, are expected to behave as hinges. (Flores et al. 2008) In
this way we can determine that the regions limited by residues 113-117 and 220222 will act as hinges. The spatial location of these residues can be seen in (Fig.
4.2B) depicted in space filling representation. Since we were also interested in
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having a spatial description of the normal modes we needed to make use of the
Anisotropic Network Model (ANM). (Hinsen et al. 1999)
We used this method because albeit being less realistic than GNM, it is
the only possible model when assessing of directions of the motions is needed.
(Cui and Bahar 2006) Fig. 4.2C shows the global dynamics of SIRP-α as
predicted by three out of the first six modes. It is important to remark that the
almost cylindrical shape of the protein in the crystal structure yields normal
modes that are very close in energy and that describe almost the same
movement but in a different plane. In this way we have that the modes 1 and 2, 3
and 5, as well as 4 and 6 can be represented by Fig. 4.2C. The remarkable
aspect of these movements is that in all of them, the residues previously
predicted as hinges seem to have that role, separating domains which move as
rigid bodies and this dynamical domain overlap almost perfectly with the
structural domains.

125

Fig. 4.1.- Surface Expression of CD47 and SIRPα
(A) Expression profiles of human cells from different hematopoietic cells show
relative number of CD47 and SIRPα surface expression taken from flow
f
cytometry using antibodie
antibodies against the specific ligands (n=3). (B) The ratio of
CD47 to SIRPα of Non
Non-professional phagocytes, Mesenchymal Stem Cells
(passage 4, n=2) and Human lung adenocarcinoma
adenocarcinoma, was determine from flow
cytometry data using RBC as a ccontrol (n=4). Avg. ± SEM for all results.
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Fig. 4.2.- Cis interactions between SIRP
SIRPα and CD47 seem consistent with
computed flexibility of SIRP
SIRPα.
(A) Membrane snapshot showing computed deformation of the extracellular
region of SIRPα together with the CD47 structure (represented in yellow,
extracted from pdb code 2jjs). (B) Crystal structure of the extracellular region of
SIRP-a
a in ribbon representation: blue (C terminal - d1 domain), green (d2
domain), red (N terminal - d3 domain). In
n yellow space filling representation the
residues C-a
a carbons from Arg
Arg-114, Ala-115, Lys-116, Arg-220,
220, Val-221
Val
and
Phe-222
222 which are estimated to act as hinges. Plot is the covariance matrix of
the C-a
a atoms in 2WNG based on the lowest 10 normal modes obtained
obt
by GNM
(C) The first three distinct normal modes obtained by ANM. From left to right:
mode 1 (mode 2 is similar but in a perpedicular plane), mode 3 (mode 5 invert
rotations), mode4 (mode 6 is similar but in a perpendicular plane). In all modes
the protein behaves as a set of three rigid bodies that can rotate and bend
around the hinges.
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Fig. 4.3.- CD47-SIRPα
SIRPα Cis intereaction effect on binding of soluble humanhuman
SIRPα on THP-1
1 Macrophages
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(A) Affinity of CD47 on THP-1 macrophages wild-type, CD47 knockdowns with
antibodies against CD47 (Clones 2D3 and B6H12) at saturation levels binding to
soluble hSIRPα based on flow cytometry. Saturation binding fit gave the
indicated dissociation constant, Kd. (B) Affinity of CD47 on THP-1 macrophages
wild-type, CD47 knockdowns with 48% and 13% CD47 wild-type levels binding to
soluble hSIRPα based on flow cytometry. Saturation binding fit gave the
indicated dissociation constant, Kd. Since this is a 3D binding constant relevant
to binding in a narrow membrane gap between two cells, it is equivalent to Kd ≈ 1
molecule/[10 nm x (10 mm)2], which is the concentration of free SIRPα that
would half-saturate CD47 on a surface. (C) Dissociation constant was plotted as
a function of percentage of wild-type CD47 expression and plotted on a linear
scale (R2 = 0.99). Competitive binding model for cis/trans interaction of CD47SIRPα
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THP-1
1 depends on pTyr Signaling
Fig. 4.4.- CD47 expression levels on THP
(A) CD47 was knockdow
knockdown by lentivirus to various efficiency
ency in THP-1
THP
macrophages. From macrophage lysates, SIRP
SIRPα was immunoprecipitated with
anti-SIRPα (SE7C2 clone) and immunoblotted for phospho
phospho-tyrosine
tyrosine and total
SIRPα (C-20
20 clone) for normalization. (B) Quantification
antification of the immunoblotted
data was plotted as a function of the % of wild
wild-type
type CD47 expression levels and
the fit of the data gave a linear relationship (R2=0.99) that depends on the CD47CD47
SIRPα Cis interaction without the presences of targets.
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Fig. 4.5- Reduction of CD47
CD47-SIRPα Cis Effect on phagocytosis in THP-1
THP
Macrophages
(A) IgG-opsonized
opsonized sheep RBC (ShRBC) and human RBC (HuRBC) or (B) IgGopsonized 2.1 µm
m particles with or without hCD47 targets were used for
phagocytosis studies with wild
wild-type
type (black bar) and 13% CD47 levels of wild-type
wild
(white bar) THP-1
1 macrophages. The ratio of ingested particles per phagocytes
shown are based on randomly
andomly selected phase contrast microscopy images with
200 phagocytes counted (n ≥ 3, ± SD).
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Fig. 4.6- CD47-SIRPα
α Trans Interaction Reduced by Cis
(A) CHO cells expressing human CD47
CD47-GFP
GFP were labeled with anti-Human
anti
CD47 (clone 2D3), detected us
using
ing AlexaFluor 647 secondary antibody, showing
that the fusion is targeted to the membrane and the Ig domain is accessible to
antibodies and co-localized
localized (white arrows), but not present with cells coco
expressing full length human SIRP
SIRPα. CHO cells expressing hCD47-GFP
hCD47
with or
without hSIRPα were labeled with (B) anti-HuCD47
HuCD47 (clone 2D3) or (C) soluble
hSIRPα were analyzed by flow cytometry. The flow cytometry log-log
log
data is
replotted on linear scales to determine binding slopes as a function of hCD47
GFP Signal
al to the respective bound ligand signal.
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Fig. 4.S1.- Professional Phagocyte CD47
CD47-SIRPα expression
Flow cytometry data shows binding of anti
anti-CD47
CD47 antibody, B6H12 binding
difference, but no difference in binding of anti
anti-SIRPα antibody, SE7C2 in THP-1
THP
wild-type
type and cells expressing 13% wild
wild-type CD47 levels.
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Fig. 4.S2.- Non-professional
professional phagocyte CD47
CD47-SIRPα expression
Flow cytometry data shows binding of anti
anti-CD47
CD47 antibody, B6H12 and antianti
SIRPα antibody, SE7C2 show different levels of either CD47 or SIRPα
SIRP profiles
for non-professional
professional phagocytes (e.g. red blood cells (RBC), Mesenchymal stem
cells (MSC), and lung carcino
carcinoma epithelial cells (A549).
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Fig. 4.S3.- CD47 Knockdown in THP
THP-1 Phagoctyes
(A) CD47 knockdown in THP
THP-1
1 macrophages was detected with anti-human
anti
CD47 (FITC) showing the extent of CD47 knockdown efficiency using different
lentiviral ShRNA targets against CD47 and (B) SIRPα expression levels was
detected using anti-SIRP
SIRPα (SE7C2) for each
ch of the CD47 knockdown THP-1
THP
macrophages using flow cytometry

135

Fig. 4.S4.- Association rate of CD47 in trans
Association rate of CD47 binding via trans in wild-type macrophages show a
slower binding rate compared to 13% CD47 wild-type levels based on flow
cytometry . Saturation association binding fit gave the indicated constant, kon.
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Fig. 4.S5.- Effect of mock lentivirus knockdown on phagocytosis
(A) IgG-opsonized
opsonized Sheep RBC were incubated with wild
wild-type
type and mock shRNA
lentivirus knockdown THP
THP-1
1 macrophages and allowed to phagocytose as
described in Materials and Methods. Phagocytosis of Sheep RBC was measured
as the ratio of ingested RBC per phagocytes with 200 phagocytes counted (n≥3,
(n
±SD). (B) THP-1
1 wild
wild-type
type cells have higher ratio of CD47-to-SIRP
CD47
while
knockdowns with 13% wild
wild-type CD47 the number of SIRPα molecule dominate
based on flow cytometry results
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SIRPα
Fig. 4.S6.- CHO Expression System of CD47 and SIRP
Flow cytometry data of CHO cells expressing CD47
CD47-GFP
GFP only detected with
binding with (A) soluble SIRP
SIRPα-GST or (B) antibodies against CD47 (Clones
6H9, 2D3, and B6H12). (C) CHO expression of CD47-GFP
GFP and SIRPα
SIRP was
confirmed by GFP and anti
anti-SIRPα antibody, P3C4.
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CHAPTER 5 – The Role of “Self signal” on Neutrophil
attachment-migration on a surface and phagocytosis of
synthetic microbeads.
Pia L. Rodriguez, Luke Witherspoon and Dennis E. Discher

L. Witherspoon helped with the phagocytosis and migration measurement.
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Abstract

The ability of a cell to distinguish foreign cells from “self” cells is required
for a healthy, functioning immune system. One mechanism through which cells
appear able to differentiate between “self” and foreign cells is through the surface
protein CD47. In previous chapters we have shown that synthetic beads labeled
with CD47are able to remain in circulation far longer than unlabeled ones. One
drawback to CD47 labeling is that it may be species-specific: one individual’s
CD47 interacting with their own receptor Sirpα may not prevent an immune
response in another individual. This chapter will specifically characterize the
interaction of different neutrophil hSirpα with the “self” peptide and with hCD47 in
an attempt to determine the effects of this surface interaction on cell attachment,
and the transmigration and phagocytosis of synthetic microbeads.

5.1 – Introduction

The ability of a cell to identify foreign cells from “self” cells is a requirement
for a healthy, functioning immune system. Without such a mechanism in place,
our immune system, and the cells that compose it, would inappropriately attack
normal tissues. Tissue or medical device rejection in implantations is a constant
concern, and patients are placed on immunosuppressive therapy to prevent
immune rejection of these foreign entities.
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One mechanism through which cells appear able to differentiate between
“self” and foreign is through the surface cellular ligand CD47 (Tsai 2010). CD47SIRPα interactions mediate the ability of CD47 to function as a marker for
macrophages to suppress phagocytosis (Matozaki 2009). CD47 has also been
implicated in cell migration, (Lindberg 1996), axon extension (Miyashita 2004),
and T cell co stimulation (Reinhold 1997). Furthermore, immuno-depletion of
either CD47 or SIRPα leads to an impairment of neutrophil ability to migrate over
cell mono-layers (Parkos 1996, Liu 2002). However, recent studies of the role of
CD47 expression on normal or leukemic hematopoietic stem and progenitor
cells, which are also physiologically migrating, does not support a role for CD47
in the migration phase of mobilization (Jaiswal 2009).
Neutrophils are the most abundant white blood cell in mammals and are
an essential part of the innate immune response. They are typically present in
the bloodstream, and are among the first cells to be recruited to sites of
inflammation as a result of infection (Smith 1994). Neutrophils play a central role
in host defense by migrating to the site of infection. Neutrophils mature in the
bone marrow before entering circulation, where they remain for 4-10 hours
before exiting to tissue pools where they survive for another1 to 2 days (Smith
1994).

Although estimates vary, neutrophils are produced in healthy human

bone marrow at a rate of 1011 cells per day, although infection can drastically
increase (10x) the number of neutrophils produced (Cannistra 1988). At sites of
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inflammation they congregate and adhere to extracellular matrix (ECM)
components such as laminin and fibronectin (Cronstein 1993). As part of the
innate immune response neutrophils then phagocytose pathogens. Neutrophils,
as with all phagocytic immune cells, are strongly influenced to phagocytose by
the presence of opsonins, such as antibodies, highlighting the cooperative nature
of the innate and adaptive immune responses (Smith 1994).
The mechanism through which receptor-ligand signaling interactions at the
neutrophil surface can regulate transmigration and ultimately inflammatory
diseases remains poorly understood. CD47 has been shown to regulate the rate
of neutrophil transmigration in mice infected with bacteria as well as across cell
monolayers and matrix (Cooper 1995, Parkos 1996, Chin 2009). In addition,
CD47 has been implicated in multiple cellular functions in addition to its role as
marker of ‘self’ (Oldenborg 2000), such as platelet activation (Chumg 1997),
macrophage multinucleation (Han 2000), immune cell apoptosis (Pettersen
1999), and dendritic cell maturation (Demeure 2000). However, CD47 signaling
pathways in transmigration have not been clearly elucidated. Furthermore, the
identification of the contribution of the CD47-SIRPα pathway to inflammatory cell
attachment to different surfaces remains unclear. Recent studies

have

suggested that polyurethane slabs coated with hCD47 inhibit polymer oxidation
in vivo (Stachelek 2011), indicating that this ‘Marker of Self’ could passivate the
inflammatory response.
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5.2 – Results

5.2.1 – Effect of “self”-peptide on Phagocytosis by Neutrophils
For all assays the target number of observed neutrophils was 200, and
each sample was examined until this number had been reached or the entire
sample had been examined. To ensure no “double” counting could occur the
samples were searched in a grid pattern that ensured no field of view was visited
twice. Following imaging, each photo of a neutrophil was made into a composite
image of all three fields using ImageJ Software and the number of microbeads
that

were

phagocytized

were

counted

to

generate

a

phagocytized

microbead:neutrophil ratio, representative image shown in Fig. 5.S1. Neutrophils
had originally been kept in 10% FBS in non-HEPES CO2 independent media, but
this led to relatively low levels of phagocytosis. To attempt to increase
phagocytosis the media was changed to 50% FBS in non-HEPES CO2
independent media. This led to a 2.4 fold increase in phagocytosis over
neutrophils tested in 10% serum (Fig. 5.S2)
We found that in 50% FBS in non-HEPES CO2 independent media there
was no difference in phagocytosis of peptide-beads as compared to control
beads after 1 hour (Fig. 5.1), (student’s t-test, p>0.05). Further experiments will
be necessary to rule out the effect that “self” peptide had on phagocytosis in
neutrophils.
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5.2.2 – Effect of Sirpα polymorphism in Neutrophil attachment and
migration on glass surfaces.
Similar to our hypothesis that CD47-labeled microbeads may decrease the
phagocytosis response, we wanted to evaluate neutrophils’ ability to migrate and
adhere to CD47 labeled substrates. This assay had to be designed to allow for
neutrophils to access to both CD47 labeled substrate (CD47 + BSA), as well as
control (BSA-only) labeled substrate (Fig. 5.2).

5.2.3 – Analysis of Migration Abilities
First we characterized how the neutrophils responded to BSA substrates
before we could evaluate whether or not CD47 labeling changed this response.
When neutrophils were present on the BSA substrate they appeared to adhere
strongly and generally stopped moving significantly after 5 minutes of exposure
to the BSA substrate. When a scratch was made on the slide, the neutrophils in
the affected area were unable to adhere within such a timeframe and began to
float, similarly to the RBCs still present in the solution.

5.2.4 – Effect of Neutrophils from diverse geographic populations in
attachment and migration on CD47-Labeled Substrate
Although neutrophils had no response to CD47 labeled synthetic beads,
we observed a very distinct response to CD47 labeled substrates. Neutrophils
rarely attached to these surfaces, and if they did attach they migrated less and
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often detached from the surface. This was very encouraging, as reduced
attachment of neutrophils would be a desirable effect of CD47 labeling on
xenographic transplants (Zehr 1994). It is unclear why neutrophils would behave
differently between CD47 labeled substrates and synthetic beads.
Using both commercially available HL60 neutrophils as well as primary
donor neutrophils, Stachelek et al demonstrated that CD47 labeling reduced
neutrophil attachment in fluid flow experiments (Stachelek 2011). The
observations from our study thus provide further evidence that neutrophils show
reduced attachment and migratory response to CD47-labeled substrates. The
differences we observed between some donors may be attributed to
polymorphisms in SIRPα observed across different geographic populations
(Takenaka 2007).
Indeed, donors of European descent were the most CD47-responsive,
while donors of Indian descent possessed the only neutrophils observed to be
able to move on CD47 surfaces (non significant differences between BSA and
CD47/BSA surface), suggesting polymorphisms in SIRPα may affect CD47
responsiveness (Table 5.1).
Although our observations of reduced migration on CD47 surfaces were
similar to those of Stachelek et al, our study differed somewhat in respect to their
observations of what occurs when neutrophils were blocked for either CD47 or
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SIRPα. We found that when CD47 was blocked, our donor neutrophils behaved
identically to our control neutrophils, whereas Stachelek et al found CD47blocked neutrophils to have reduced activity and binding efficiency to most
surfaces (Stachelek 2011). Perhaps the difference can be explained by their use
of HL60 neutrophils for this experiment, compared to our use of primary noncancerous donor neutrophils.

5.3 – Discussion

Three different approaches to neutrophil isolation were evaluated before
ultimately settling on one method for analysis. One of the best characterized
means for extraction of neutrophils is through the protocol published by Oh et al,
which uses commercially available separation media and centrifugation to
separate blood into distinct bands (Oh 2008). This protocol requires high
volumes, which meant we would need to obtain blood from a blood depository.
Therefore we decided to pursue a protocol (detailed in materials and methods)
based on blood obtained from a finger prick. This protocol yields a lower purity of
neutrophils, but is easier to plan and more cost effective, allowing us to run
several assays over the course of a day.
Although the effect of “Self” markers in neutrophil phagocytosis and
transmigration remains unclear, we have provided insight on the different effects
that human SIRPα polymorphisms could have on Neutrophil behavior on
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synthetic surfaces coated with recombinant hCD47. These surfaces mimic
neutrophil flow through vessel walls before attachment and spreading into
endothelial cells, infection sites, synthetic polymer slabs or biomaterials.
From the 10 Sirpα polymorphisms we identified using HapMap data
(www.hapmap.org) along with the structural analysis of the paired SIRPα-CD47
protein (Hatherley 2008), we discovered in Chapter 2 that there are two SIRPα
variants (5 and 7) with approximately 20-40 fold reduced binding affinity to
hCD47. It seems very plausible that macrophages expressing SIRPα variants 5
and 7 would not recognize “self” cells expressing hCD47, and would therefore be
prone to clearing “self” cells. Our results in Table 5.1 demonstrate that, assuming
comparable hSIRPα expression on all cells tested, neutrophils from donors who
are most likely to express variant 7 based on their geographic origin do not
strongly bind to hCD47, and their surface attachment and spreading is unaffected
by the presence of our recombinant protein.

5.4 – Materials and Methods

5.4.1 – Neutrophil Extraction
A reusable needle pen (BD Biosciences) was used with disposable 30
gauge needles (BD Biosciences). The pen was completely sterilized after each
use with 70% ethanol wipes and allowed to dry. The donor’s index finger was
cleaned with 70% ethanol and allowed to dry. Following this sterilization,
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constricting pressure was applied around the donor’s finger to condense blood
into the tip of the finger. Blood was extracted with a 200µl pipette and placed into
a solution of 0.5M EDTA (Gibco)/ 1x DPBS solution (Gibco) in a 0.5ml Eppendorf
tube. Blood was extracted until the injection site stopped bleeding, which
generally yielded ~200µl of blood. The blood sample was then spun in a
centrifuge (Spectrafuge 24D) at 5000 rpm for 5 minutes. The upper plasma/PBS
layer was then removed and 500µl of RBC lysis buffer (Sigma) was added. Cells
were allowed to lyse for 5 minutes. The cells were then centrifuged for 3 minutes
at 3000rpm. The supernatant from this tube was then removed and allowed to
continue lysing until the solution appeared see-through (5-7 minutes) in a 37°C
incubator. This tube underwent a subsequent centrifugation step (5 minutes at
5000rpm) to pellet the neutrophils. The pellet was then re-suspended in 50µl
50% FBS (Gibco) / non-HEPES CO2 independent media (Gibco) and placed in
an incubator at 37°C.

5.4.2 – Neutrophil Phagocytosis Assay
To analyze neutrophil phagocytosis 2.1 µm opsonized (IgG) microbeads
(Spherotech) were blocked by washing 3 times in a 1% BSA – 1 x DPBS
solution, followed by centrifugation for 6 minutes at 10,000 rpm. The ratio used
was approximately 20:1 microbeads to neutrophils.
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Following blocking, beads were incubated in a 6 µg/ml solution of
conjugated anti-streptavidin (Rockland) in PBS for 30 minutes and then spun
down for six minutes at 10,000 rpm and re-suspended in 1 x PBS. Opsonin (IgG
)+, CD47- peptide-labeled beads were then incubated with 2uM of CD47 derived
peptide in PBS overnight at room temperature and then spun down for 5 minutes
at 7,000 rpm and re-suspended in 1 x PBS. Following CD47-peptide labeling the
beads were incubated in with anti-streptavidin (Rockland) in PBS for 30 minutes
and then spin down for 5 minutes at 7000 rpm and resuspended in 1 x PBS.
Extracted neutrophils were then placed in 2-chambered plates (Labtech) and
50% FBS / non-HEPES CO2 independent media were added. The cells were
then placed in an incubator (37°C) for 1 hour. Afte r 1 hour had elapsed following
microbead addition, the cells were fixed in 0.4% formaldehyde for 10 minutes at
room temperature.
The cells were then placed into a 1.5ml Eppendorf tube and centrifuged at
5000rpm for 5 minutes. The supernatant was removed and the pellet was
resuspended in 500ul PBS.
The cells were then incubated for 20 minutes at room temperature with
anti-rabbit secondary IgG antibody (Thermo Scientific). Cells were then imaged
and analyzed in the bright field, FITC, and TRITC spectrums. Each sample well
was searched for any neutrophils that were present and each was imaged first in
bright field, then in FITC to see if any microbeads had been phagocytized, and
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then finally in TRITC to analyze secondary antibody staining. Since only nonphagocytosed microbeads could be bound by secondary antibody, this presented
a good mechanism to ensure microbeads observed to be attached to or inside of
a neutrophil had indeed been phagocytized and internalized. The number of
phagocytosed microbeads was counted to calculate a phagocytosed microbead:
neutrophil ratio.

5.4.3 – Migration Assays
Slides were coated with a 1% BSA solution. We then added an aliquot of
neutrophils in suspension to these slides and took sequential images to track
their migration ability.

5.4.4 – Neutrophil Imaging
Images were acquired with an inverted microscope (IX71; Olympus) with a
60x (oil, 1.4 NA) objective using a Cascade CCD camera (Photometrics). Image
acquisition was performed with Image Pro software (Media Cybernetics, Inc.).
Time-lapse imaging was performed using a heated stage (Ibidi GmbH) at 37° C
in non-HEPES CO2 independent media. Image acquisition was performed with
Image Pro software (Media Cybernetics, Inc.). All subsequent image analysis
was done using ImageJ.
In the migration assay, randomly selected cells were followed from their
center of mass from time zero up to 45 minutes in 3-minute increments.The total
154

migration distance was obtained by adding the measured distances between the
center of mass of each selected neutrophil in the field of view

5.4.5 – CD47 Substrate
One side of a BSA coated slide was labeled with 2uM of full length CD47
in PBS and allowed to dry (we followed Stachelek et al.’s recommendation on the
amount of hCD47 needed to observe an effect on neutrophil response, >16 ng
CD47/cm2). Using the same neutrophil extraction procedure, 10µl of the
neutrophil solution was pipetted onto the center of the CD47 slide. A cover slip
(Fisher brand) was then put on the slide, and sealed with nail polish. Cells were
then imaged for 45 minutes. No cell death was observed in this time frame due to
nail polish toxicity.

5.4.6 – Protein Blocking Experiments
For protein blocking experiments anti-CD47 (BD Biosciences,B6H12), or
anti-SIRPα (Santa Cruz, SE7C2) were used. Antibodies were allowed to incubate
with neutrophils in media at room temperature for 30 minutes. Blocking by
antibodies was confirmed through fluorescence microscopy where imaged
neutrophils were examined for appropriate fluorescent signals.
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Fig. 5.1.- Self- beads don’t inhibit Neutrophil Phagocytosis
When hCD47-derived peptide beads were used, there was no significant
(p>0.05) change in phagocytosis compared to control labeled beads.
Phagocytosis rates (beads phagocytized/neutrophil number) were compared
between three samples from the same donor for each condition. Total neutrophils
counted: Control trials n =748, Peptide trials n=681.
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Fig. 5.2.- Schematic representation of Migration Assay Protocol
(Described in more detail in Material and Methods)
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hSIRPα variants

Migration (um over 45 minutes)
BSA Surface

CD47/BSA Surface

*Donor 1: V1, V2, V3

66.54 ± 12.06

0

Donor 2: V4, V7, V8, V2

26.77 ± 2.4

16.55 ± 5.1

*Donor 3: V1, V2, V3

117.92 ± 32.6

31.84 ±12.1

*Donor 4: V1, V2

32.26 ± 11.1

0

Donor 5: V2, V4, V7,V8

41.19 ± 4.3

63.86 ±8.7

*Donor 6: V2,V3

13.35 ± 3.2

0

*Donor 7: V9, V10

23.56 ± 5.9

0

Table 5.1: Effect of SIRPα Polymorphisms on Migration in human
Neutrophils.
(B)
The effect of SIRPα on migration of neutrophils from various donors was
tested as previously detailed in Fig. 5.2. Based on the human HapMap data
(www.hapmap.org) we defined the possible SIRPα variants (denoted as V1- V10
in the table above) that donors from each geographical location could possess.
Donors 1 (L.W, n = 6 cells), 3 (J.S, n = 4 cells) and 4 (N.S, n = 4 cells) are of
European descent. Donors 2 (P.S, n = 6 cells) and 5 (D.D., n = 4 cells) are of
Indian/Asian descent. Donor 6 (A.B., n = 3 cells) is of Middle Eastern descent
and Donor 7 (T.H., n = 4 cells) is of Japanese descent. All data are mean ±SEM.
(* p < 0.05 between surfaces for each donor).
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Fig. S5.1.- Neutrophil Phagocytosis
Phagocytosis was confirmed using a secondary antibody incapable of cell entry.
Image represents a composite image showing bright field, FITC, and TRIC
fluorescence. Phagocytized beads fluoresce only in the FITC spectrum (green),
while beads outside of the cell fluoresce in both the FITC and TRITC (red)
spectra creating a yellow color. Image taken with 60x objective and a digital
zoom of 1.5x.
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Fig. S5.2.- Serum Level Affects Neutrophil Phagocytosis
Changing the serum concentration to 50% FBS led to a 2.4 fold increase in
phagocytosis of synthetic 2.1um microbeads by neutrophils, as compared to
neutrophils in media containing 10% FBS serum. 50% serum phagocytosis rates
are normalized to 10% serum phagocytosis rates
rates. Total neutrophils counted:
10% FBS n =210,, 50% FBS n=217.
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CHAPTER 6 – CONCLUSIONS AND FUTURE WORK
In this dissertation we have shown that the membrane protein CD47 acts
as a ‘Marker of Self’ that impedes phagocytosis of self cells by signaling through
a species-specific, highly polymorphic receptor, SIRPα. In each of the preceding
chapters we have described various findings that have supported this general
notion.
In Chapter 2, we introduced our reductionist approach of designing
minimal “self” peptides derived from human-CD47, synthesized with anchoring
groups, and attached to virus-size nanoparticles for injection into NOD.SCID
gamma (NSG) mice. We found only a weak affinity of hCD47 for NSG-SIRPα, but
that was still within the broad range (0.1~5 µM) of affinity of the different humanSIRPα variants. The hCD47-peptides delayed splenic clearance of particles by
macrophages with an exponential increase in persistence in circulation. Our
reductionist approach thus highlighted the importance of a human ‘Marker of
Self’.
In Chapter 3, we applied our reductionist approach to a potential
therapeutic application. We showed that “self”-beads and hCD47-beads led to a
16- to 22-fold enhancement of the near-infrared imaging of human tumor
xenografts. We also showed that hCD47-beads could shrink lung tumor cells with
similar efficiency as the widely used current standard Cremophor® EL-Paclitaxel
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(Taxol) treatments, but without the noted toxicity imparted by the Cremophor® EL
excipient. We also developed an antibody-targeting approach using this “self”
peptide, which allowed us to successfully target the human lung cancer cells with
a biotinylated anti-hCD47 antibody. This antibody resulted in more efficient
delivery to the tumor site, leading to suppression in tumor growth in just one day.
In Chapter 4, we moved into the molecular level in an effort to understand
the low affinity of the signal regulatory protein (SIRPα) to hCD47. We found that
this low affinity was necessary to allow for rapid exchange of CD47-SIRPα from
an intracellular cis to an intercellular trans interaction. Further confirmation of this
competitive binding behavior was demonstrated through measurement of the
association constant, kon, which exhibited a slower rate for wild-type
macrophages. This suggested that the availability of CD47 to interact in trans
was influenced by the amount of CD47 that was occupied in cis interactions. The
CD47-SIRPα cis interactions appear to partially hinder phagocytosis of foreign
particles, but at the same time it is important for macrophages to maintain their
own display of the “self” signal to prevent their own phagocytic clearance by
other macrophages.
Finally, in Chapter 5 we extended our analysis of marker of “self” to the
case of neutrophil transmigration. Our preliminary findings in this regard
suggested that the SIRPα polymorphism in the human population affects the
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migration process of neutrophils. When higher levels of neutrophil migration on a
surface were observed, there was a lower affinity of the SIRPα variants for CD47.
Taken together, the chapters of this dissertation show that we have
successfully designed a unique CD47 peptide that mimic the effect of the fulllength protein in inhibiting the uptake of nanometer scale particles by
macrophages in vivo. Our method therefore offers a very attractive platform for
potential biomedical applications. The antibody targeting approach developed
here revealed the importance and utility of a human marker of “self” in improving
drug delivery on nanobeads, which could lead to safer therapies. It remains to be
seen how our reductionist approach will perform as a human clinical drug
delivery carrier, e.g. filomicelles or toroidal polymers. Similarly, it would be
interesting to apply our methods to tissue xenotransplantation.

We hope to

continue investigating these issues in future research.
Xenograft rejection remains as a major obstacle to clinical transplantation
in current medicine. We hope that the methods and evidence provided in this
dissertation will contribute to a more thorough understanding of this problem.
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